Team 5: Atherothrombotic Disease in Heart and Brain

Group leader: Gabriel STEG


Staff of the team

Name
Position
Phone
Email
AMARENCO PierrePU-PH01.40.25.87.25pierre.amarenco@bch.aphp.fr
AMGOUD YasmineDoctorant yas-a@live.com
BACHER AnneARC
BENTARFAYA IkramMaster 2
BOUFFARD CatherineInfirmiere catherine.bouffard@aphp.fr
CHOQUEUX ChristineIE01.40.25.86.12christine.choqueux@inserm.fr
CODOGNO IsabelleARC isabelle.codogno@gmail.com
CUNGH Hong AnhAHU
DUCROCQ GregoryDoctorant gregory.ducrocq@aphp.fr
FABRE Jean-EtienneDR01.40.25.86.07jean-etienne.fabre@inserm.fr
FARNOUD RezaARC01.57.27.53.52reza.farnoud@bch.aphp.fr
JULIARD Jean-Michel 01.40.25.85.21jean-michel.juliard@bch.ap-ho-paris.fr
KLEIN IsabellePH01.40.25.82.45isabelle.klein@bch.aphp.fr
LAVALLEE PhilippaMCUPH01.40.25.70.33philippalavallee@yahoo.fr
LESECHE Guy PU-PH guy.leseche@aphp.fr
LONGROIS DanPU-PH01.40.25.74.27dan.longrois@bch.aphp.fr
LOUEDEC LilianeAI01.40.25.86.14liliane.louedec@inserm.fr
MANI SalmaDoctorant
MAWHIN Marie-AnneDoctorant01.40.25.86.06marie-anne.mawhin@inserm.fr
MUHAMMAD ABDELMONEIM HebaDoctorant
NOREL Xavier IE01.40.25.75.29xnorel@hotmail.com
OUGHIRI MeryemARC meryem_11@hotmail.fr
SIMON TobassomePU-PH tabassome.simon@aphp.fr
SONNEVILLE RomainPH01.40.25.61.39romain.sonneville@bch.aphp.fr
SPIELER Jean-FrançoisECO01.40.25.87.28jean-francois.spieler@bch.aphp.fr
STEG Philippe GabrielPU-PH01.40.25.73.25gabriel.steg@bch.aphp.fr
TCHITCHINADZE Maria 01.40.25.68.14maria.tchitchinadze@bch.aphp.fr
TOUBOUL Pierre-JeanPATT01.40.25.87.25pjtw@noos.fr
YUNG Sonia Master 2
ZIRKA GaiaMaster 2 gaiazirka@gmail.com

Project outlines

ClinicalresearchTeam 5 “Translational research on cardio- and cerebrovascular disease” started with an innovative collaboration of cardiologists and neurologists (formerly within the “clinical research on atherothrombosis” team) implemented by basic science researchers, coming from the former team on “Vascular Remodelling”. Our projects are focussed on 1/ international clinical trials assessing medical strategies and new therapies in coronary artery disease and cerebrovascular disease, particularly acute coronary syndromes and stroke, and 2/ on translational research aiming to uncover new biological markers of atherothrombosis in humans as a basis for new diagnostic/theranostic tools, but also for developing new therapeutic tools (in particular HDL-based therapies).

There is a dire need for therapies to help address the cardiovascular consequences of the diabetes and obesity epidemic. While important, this is not limited to the development of more potent and safer agents to prevent thrombosis, stabilize or prevent atherosclerosis, or treat hyperglycemia. The potential hazards (on cardiovascular mortality) of aggressive management of hyperglycemia have emphasized the need to fully assess the cardiovascular impact of antidiabetic drugs. Recent clinical trials also underlined the importance of rigorous evaluation of the clinical effectiveness of routine therapeutic strategies. Future treatments will need to demonstrate safety and cost-effectiveness in addition to efficacy. Our aim is to focus on new, effective, safe, affordable and easily implementable therapeutic strategies for atherothrombosis and diabetes.


Publications (2012->Today)

2017

1.
Abboud H, Sissani L, Labreuche J, Arauz A, Bousser M-G, Bryer A, Chamorro A, Fisher M, Ford I, Fox KM, Hennerici MG, Lavados PM, Massaro A, Mattle HP, Munoz Collazos M, Rothwell PM, Steg PG, Vicaut E, Yamouth B, Amarenco P, Registry O, Investigators PT. 2017. Specificities of Ischemic Stroke Risk Factors in Arab-Speaking Countries. Cerebrovascular Diseases (Basel, Switzerland) 43:169–177.
1.
Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Hill MD, Jonasson J, Kasner SE, Ladenvall P, Minematsu K, Molina CA, Wang Y, Wong KSL, Johnston SC, Committee SS, Investigators. 2017. Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. The Lancet Neurology 16:301–310.
1.
Amarenco P, Kim AS. 2017. Aspirin’s Benefits Were Previously Underestimated and Are Primarily Accrued in the Acute Setting. Stroke 48:1438–1440.
1.
Amarenco P, Sissani L, Labreuche J, Vicaut E, Bousser MG, Chamorro A, Fisher M, Ford I, Fox KM, Hennerici MG, Mattle H, Rothwell PM, Steg PG, Diener H-C, Sacco RL, Greving JP, Algra A, Perform, Committees PR, Investigators. 2017. The Intracranial-B2LEED3S Score and the Risk of Intracranial Hemorrhage in Ischemic Stroke Patients Under Antiplatelet Treatment. Cerebrovascular Diseases (Basel, Switzerland) 43:145–151.
1.
Boccara F, Miantezila Basilua J, Mary-Krause M, Lang S, Teiger E, Steg PG, Funck-Brentano C, Girard P-M, Costagliola D, Cohen A, Guiguet M, on behalf the P-HIV investigators. 2017. Statin therapy and low-density lipoprotein cholesterol reduction in HIV-infected individuals after acute coronary syndrome: Results from the PACS-HIV lipids substudy. American Heart Journal 183:91–101.
1.
Bouglé A, Foucrier A, Dupont H, Montravers P, Ouattara A, Kalfon P, Squara P, Simon T, Amour J, i D study group. 2017. Impact of the duration of antibiotics on clinical events in patients with Pseudomonas aeruginosa ventilator-associated pneumonia: study protocol for a randomized controlled study. Trials 18:37.
1.
Costa F, van Klaveren D, James S, Heg D, Räber L, Feres F, Pilgrim T, Hong M-K, Kim H-S, Colombo A, Steg PG, Zanchin T, Palmerini T, Wallentin L, Bhatt DL, Stone GW, Windecker S, Steyerberg EW, Valgimigli M, Investigators P-DS. 2017. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials. Lancet (London, England) 389:1025–1034.
1.
Dahan K, Debiec H, Plaisier E, Cachanado M, Rousseau A, Wakselman L, Michel P-A, Mihout F, Dussol B, Matignon M, Mousson C, Simon T, Ronco P, Group GS. 2017. Rituximab for Severe Membranous Nephropathy: A 6-Month Trial with Extended Follow-Up. Journal of the American Society of Nephrology: JASN 28:348–358.
1.
Ducrocq G, Schulte PJ, Budaj A, Cornel JH, Held C, Himmelmann A, Husted S, Storey RF, Cannon CP, Becker RC, James SK, Katus HA, Lopes RD, Sorbets E, Wallentin L, Steg PG. 2017. Balancing the risk of spontaneous ischemic and major bleeding events in acute coronary syndromes. American Heart Journal 186:91–99.
1.
Fabris E, Kilic S, Van’t Hof AWJ, Ten Berg J, Ayesta A, Zeymer U, Hamon M, Soulat L, Bernstein D, Anthopoulos P, Deliargyris EN, Steg PG. 2017. One-Year Mortality for Bivalirudin vs Heparins Plus Optional Glycoprotein IIb/IIIa Inhibitor Treatment Started in the Ambulance for ST-Segment Elevation Myocardial Infarction: A Secondary Analysis of the EUROMAX Randomized Clinical Trial. JAMA cardiology.
1.
Faggioni M, Baber U, Sartori S, Giustino G, Cohen DJ, Henry TD, Farhan S, Ariti C, Dangas G, Gibson M, Giacoppo D, Krucoff MW, Aquino M, Chandrasekhar J, Moliterno DJ, Colombo A, Vogel B, Chieffo A, Kini AS, Witzenbichler B, Weisz G, Steg PG, Pocock S, Mehran R. 2017. Incidence, Patterns, and Associations Between Dual-Antiplatelet Therapy Cessation and Risk for Adverse Events Among Patients With and Without Diabetes Mellitus Receiving Drug-Eluting Stents: Results From the PARIS Registry. JACC Cardiovascular interventions 10:645–654.
1.
Feldman L, Steg PG, Amsallem M, Puymirat E, Sorbets E, Elbaz M, Ritz B, Hueber A, Cattan S, Piot C, Ferrières J, Simon T, Danchin N, investigators F-M. 2017. Editor’s Choice-Medically managed patients with non-ST-elevation acute myocardial infarction have heterogeneous outcomes, based on performance of angiography and extent of coronary artery disease. European Heart Journal Acute Cardiovascular Care 6:262–271.
1.
Foudi N, Ozen G, Amgoud Y, Louedec L, Choqueux C, Badi A, Kotelevets L, Chastre E, Longrois D, Norel X. 2017. Decreased vasorelaxation induced by iloprost during acute inflammation in human internal mammary artery. European Journal of Pharmacology 804:31–37.
1.
Goodman SG, Nicolau JC, Requena G, Maguire A, Blankenberg S, Chen JY, Granger CB, Grieve R, Pocock SJ, Simon T, Yasuda S, Vega AM, Brieger D, Investigators TS. 2017. Longer-term oral antiplatelet use in stable post-myocardial infarction patients: Insights from the long Term rIsk, clinical manaGement and healthcare Resource utilization of stable coronary artery dISease (TIGRIS) observational study. International Journal of Cardiology 236:54–60.
1.
Hagström E, Held C, Stewart RAH, Aylward PE, Budaj A, Cannon CP, Koenig W, Krug-Gourley S, Mohler ER, Steg PG, Tarka E, Östlund O, White HD, Siegbahn A, Wallentin L, Investigators S. 2017. Growth Differentiation Factor 15 Predicts All-Cause Morbidity and Mortality in Stable Coronary Heart Disease. Clinical Chemistry 63:325–333.
1.
Hobeanu C, Lavallée PC, Rothwell PM, Sissani L, Albers GW, Bornstein NM, Caplan LR, Donnan GA, Ferro JM, Hennerici MG, Labreuche J, Molina C, Steg PG, Touboul P-J, Uchiyama S, Vicaut É, Wong LKS, Amarenco P, Investigators TIa org. 2017. Symptomatic Patients Remain at Substantial Risk of Arterial Disease Complications Before and After Endarterectomy or Stenting. Stroke 48:1005–1010.
1.
Lim AI, Li Y, Lopez-Lastra S, Stadhouders R, Paul F, Casrouge A, Serafini N, Puel A, Bustamante J, Surace L, Masse-Ranson G, David E, Strick-Marchand H, Le Bourhis L, Cocchi R, Topazio D, Graziano P, Muscarella LA, Rogge L, Norel X, Sallenave J-M, Allez M, Graf T, Hendriks RW, Casanova J-L, Amit I, Yssel H, Di Santo JP. 2017. Systemic Human ILC Precursors Provide a Substrate for Tissue ILC Differentiation. Cell 168:1086–1100.e10.
1.
Lindholm D, Hagström E, James SK, Becker RC, Cannon CP, Himmelmann A, Katus HA, Maurer G, López-Sendón JL, Steg PG, Storey RF, Siegbahn A, Wallentin L. 2017. Growth Differentiation Factor 15 at 1 Month After an Acute Coronary Syndrome Is Associated With Increased Risk of Major Bleeding. Journal of the American Heart Association 6.
1.
Lindholm D, James SK, Bertilsson M, Becker RC, Cannon CP, Giannitsis E, Harrington RA, Himmelmann A, Kontny F, Siegbahn A, Steg PG, Storey RF, Velders MA, Weaver WD, Wallentin L, Investigators P. 2017. Biomarkers and Coronary Lesions Predict Outcomes after Revascularization in Non-ST-Elevation Acute Coronary Syndrome. Clinical Chemistry 63:573–584.
1.
Manzo-Silberman S, Nicaise-Roland P, Neukirch C, Tubach F, Huisse M-G, Chollet-Martin S, Abergel H, Driss F, Alfaiate T, Ajzenberg N, Steg PG. 2017. Effect of rapid desensitization on platelet inhibition and basophil activation in patients with aspirin hypersensitivity and coronary disease. European Heart Journal Cardiovascular Pharmacotherapy 3:77–81.
1.
Mazighi M, Meseguer E, Labreuche J, Miroux P, Le Gall C, Roy P, Tubach F, Amarenco P. 2017. TRUST-tPA trial: Telemedicine for remote collaboration with urgentists for stroke-tPA treatment. Journal of Telemedicine and Telecare 23:174–180.
1.
Ozen G, Norel X. 2017. Prostanoids in the pathophysiology of human coronary artery. Prostaglandins & Other Lipid Mediators.
1.
Palmerini T, Bacchi Reggiani L, Della Riva D, Romanello M, Feres F, Abizaid A, Gilard M, Morice M-C, Valgimigli M, Hong M-K, Kim B-K, Jang Y, Kim H-S, Park KW, Colombo A, Chieffo A, Ahn J-M, Park S-J, Schüpke S, Kastrati A, Montalescot G, Steg PG, Diallo A, Vicaut E, Helft G, Biondi-Zoccai G, Xu B, Han Y, Genereux P, Bhatt DL, Stone GW. 2017. Bleeding-Related Deaths in Relation to the Duration of Dual-Antiplatelet Therapy After Coronary Stenting. Journal of the American College of Cardiology 69:2011–2022.
1.
Parker WA, Bhatt DL, Prats J, Day JRS, Steg PG, Stone GW, Hamm CW, Mahaffey KW, Price MJ, Gibson CM, White HD, Storey RF, Investigators CP. 2017. Characteristics of dyspnoea and associated clinical outcomes in the CHAMPION PHOENIX study. Thrombosis and Haemostasis.
1.
Parma Z, Steg PG, Greenlaw N, Ferrari R, Ford I, Fox K, Tardif J-C, Morais J, Gamba MA, Kääb S, Tendera For The Clarify Investigators M. 2017. Differences in outcomes in patients with stable coronary artery disease managed by cardiologists versus noncardiologists. Results from the international prospective CLARIFY registry. Polish Archives of Internal Medicine 127:107–114.
1.
Potier L, Roussel R, Elbez Y, Marre M, Zeymer U, Reid CM, Ohman M, Eagle KA, Bhatt DL, Steg PG, Investigators* RR. 2017. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk. Heart (British Cardiac Society).
1.
Puymirat E, Aissaoui N, Cayla G, Lafont A, Riant E, Mennuni M, Saint-Jean O, Blanchard D, Jourdain P, Elbaz M, Henry P, Bataille V, Drouet E, Mulak G, Schiele F, Ferrières J, Simon T, Danchin N, investigators F-M. 2017. Changes in One-Year Mortality in Elderly Patients Admitted with Acute Myocardial Infarction in Relation with Early Management. The American Journal of Medicine 130:555–563.
1.
Puymirat E, Aissaoui N, Lemesle G, Cottin Y, Coste P, Schiele F, Ferrières J, Simon T, Danchin N, Investigators F-M. 2017. Long-Term Clinical Outcomes According to Previous Manifestations of Atherosclerotic Disease (from the FAST-MI 2010 Registry). The American Journal of Cardiology 119:692–697.
1.
Puymirat E, Caudron J, Steg PG, Lemesle G, Cottin Y, Coste P, Schiele F, de Labriolle A, Bataille V, Ferrières J, Simon T, Danchin N, investigators F-M. 2017. Prognostic impact of non-compliance with guidelines-recommended times to reperfusion therapy in ST-elevation myocardial infarction. The FAST-MI 2010 registry. European Heart Journal Acute Cardiovascular Care 6:26–33.
1.
Ridker PM, Revkin J, Amarenco P, Brunell R, Curto M, Civeira F, Flather M, Glynn RJ, Gregoire J, Jukema JW, Karpov Y, Kastelein JJP, Koenig W, Lorenzatti A, Manga P, Masiukiewicz U, Miller M, Mosterd A, Murin J, Nicolau JC, Nissen S, Ponikowski P, Santos RD, Schwartz PF, Soran H, White H, Wright RS, Vrablik M, Yunis C, Shear CL, Tardif J-C, Investigators SCO. 2017. Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients. The New England Journal of Medicine 376:1527–1539.
1.
Ridker PM, Tardif J-C, Amarenco P, Duggan W, Glynn RJ, Jukema JW, Kastelein JJP, Kim AM, Koenig W, Nissen S, Revkin J, Rose LM, Santos RD, Schwartz PF, Shear CL, Yunis C, Investigators S. 2017. Lipid-Reduction Variability and Antidrug-Antibody Formation with Bococizumab. The New England Journal of Medicine 376:1517–1526.
1.
Rosenzwajg M, Languille E, Debiec H, Hygino J, Dahan K, Simon T, Klatzmann D, Ronco P. 2017. B- and T-cell subpopulations in patients with severe idiopathic membranous nephropathy may predict an early response to rituximab. Kidney International.
1.
Rouzier R, Uzan C, Rousseau A, Guillot E, Zilberman S, Meyer C, Estevez P, Dupre P-F, Kere D, Doridot V, D’Halluin G, Fritel X, Pouget N, Jankowski C, Mazouni C, Simon T, Coutant C. 2017. Multicenter prospective evaluation of the reliability of the combined use of two models to predict non-sentinel lymph node status in breast cancer patients with metastatic sentinel lymph nodes: the MSKCC nomogram and the Tenon score. Results of the NOTEGS study. British Journal of Cancer 116:1135–1140.
1.
Simon T, Danchin N. 2017. Clinical Impact of Pharmacogenomics of Clopidogrel in Stroke. Circulation 135:34–37.
1.
Steg PG, Simon T. 2017. Duration of antiplatelet therapy after DES implantation: can we trust non-inferiority open-label trials? European Heart Journal 38:1044–1047.
1.
Thomas MR, Angiolillo DJ, Bonaca MP, Ajjan RA, Judge HM, Rollini F, Franchi F, Ahsan AJ, Bhatt DL, Kuder JF, Steg PG, Cohen M, Muthusamy R, Sabatine MS, Storey RF. 2017. Consistent platelet inhibition with ticagrelor 60 mg twice-daily following myocardial infarction regardless of diabetes status. Thrombosis and Haemostasis 117:940–947.
1.
Vacchina V, Séby F, Chekri R, Verdeil J, Dumont J, Hulin M, Sirot V, Volatier J-L, Serreau R, Rousseau A, Simon T, Guérin T. 2017. Optimization and validation of the methods for the total mercury and methylmercury determination in breast milk. Talanta 167:404–410.
1.
Varasteh Z, Hyafil F, Anizan N, Diallo D, Aid-Launais R, Mohanta S, Li Y, Braeuer M, Steiger K, Vigne J, Qin Z, Nekolla SG, Fabre J-E, Döring Y, Le Guludec D, Habenicht A, Vera DR, Schwaiger M. 2017. Targeting mannose receptor expression on macrophages in atherosclerotic plaques of apolipoprotein E-knockout mice using (111)In-tilmanocept. EJNMMI research 7:40.
1.
Vidal-Petiot E, Bhatt DL, Fox KM, Steg PG. 2017. Blood pressure and cardiovascular outcomes: a closer look - Authors’ reply. Lancet (London, England) 389:1296–1297.
1.
Wang Y, Minematsu K, Wong KSL, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Jonasson J, Molina CA, Johnston SC, Committee SS, Investigators. 2017. Ticagrelor in Acute Stroke or Transient Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes). Stroke 48:167–173.
1.
Welsh RC, Roe MT, Steg PG, James S, Povsic TJ, Bode C, Gibson CM, Ohman EM. 2017. Corrigendum to “A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease” [Am Heart J 181 (2016) 92-100]. American Heart Journal 184:156.
1.
Zannad F, Pfeffer MA, Bhatt DL, Bonds DE, Borer JS, Calvo-Rojas G, Fiore L, Lund LH, Madigan D, Maggioni AP, Meyers CM, Rosenberg Y, Simon T, Stough WG, Zalewski A, Zariffa N, Temple R. 2017. Streamlining cardiovascular clinical trials to improve efficiency and generalisability. Heart (British Cardiac Society).

2016

1.
Abtan J, Bhatt DL, Elbez Y, Sorbets E, Eagle K, Ikeda Y, Wu D, Hanson ME, Hannachi H, Singhal PK, Steg PG, Ducrocq G, Investigators RR. 2016. Residual Ischemic Risk and Its Determinants in Patients With Previous Myocardial Infarction and Without Prior Stroke or TIA: Insights From the REACH Registry. Clinical Cardiology 39:670–677.
1.
Aissaoui N, Puymirat E, Juilliere Y, Jourdain P, Blanchard D, Schiele F, Guéret P, Popovic B, Ferrieres J, Simon T, Danchin N. 2016. Fifteen-year trends in the management of cardiogenic shock and associated 1-year mortality in elderly patients with acute myocardial infarction: the FAST-MI programme. European Journal of Heart Failure 18:1144–1152.
1.
Amarenco P, Lavallée PC, Labreuche J, Albers GW, Bornstein NM, Canhão P, Caplan LR, Donnan GA, Ferro JM, Hennerici MG, Molina C, Rothwell PM, Sissani L, Školoudík D, Steg PG, Touboul P-J, Uchiyama S, Vicaut É, Wong LKS, Investigators TIa org. 2016. One-Year Risk of Stroke after Transient Ischemic Attack or Minor Stroke. The New England Journal of Medicine 374:1533–1542.
1.
Amarenco P, Steering Committee Investigators of the Tia org. 2016. Risk of Stroke after Transient Ischemic Attack or Minor Stroke. The New England Journal of Medicine 375:387.
1.
Arangalage D, Lepage L, Faille D, Cimadevilla C, Dilly M-P, Papy E, Alhenc-Gelas M, Ghodbane W, Nataf P, Iung B, Steg PG, Vahanian A, Ajzenberg N, Messika-Zeitoun D. 2016. Presentation, management and outcome of heparin-induced thrombocytopenia after valvular heart surgery. European Journal of Cardio-Thoracic Surgery: Official Journal of the European Association for Cardio-Thoracic Surgery 50:1132–1138.
1.
Baber U, Dangas G, Chandrasekhar J, Sartori S, Steg PG, Cohen DJ, Giustino G, Ariti C, Witzenbichler B, Henry TD, Kini AS, Krucoff MW, Gibson CM, Chieffo A, Moliterno DJ, Weisz G, Colombo A, Pocock S, Mehran R. 2016. Time-Dependent Associations Between Actionable Bleeding, Coronary Thrombotic Events, and Mortality Following Percutaneous Coronary Intervention: Results From the PARIS Registry. JACC Cardiovascular interventions 9:1349–1357.
1.
Baber U, Dangas G, Cohen DJ, Gibson CM, Mehta SR, Angiolillo DJ, Pocock SJ, Krucoff MW, Kastrati A, Ohman EM, Steg PG, Badimon J, Zafar MU, Chandrasekhar J, Sartori S, Aquino M, Mehran R. 2016. Ticagrelor with aspirin or alone in high-risk patients after coronary intervention: Rationale and design of the TWILIGHT study. American Heart Journal 182:125–134.
1.
Baber U, Mehran R, Giustino G, Cohen DJ, Henry TD, Sartori S, Ariti C, Litherland C, Dangas G, Gibson CM, Krucoff MW, Moliterno DJ, Kirtane AJ, Stone GW, Colombo A, Chieffo A, Kini AS, Witzenbichler B, Weisz G, Steg PG, Pocock S. 2016. Coronary Thrombosis and Major Bleeding After PCI With Drug-Eluting Stents: Risk Scores From PARIS. Journal of the American College of Cardiology 67:2224–2234.
1.
Bailleul C, Puymirat E, Aissaoui N, Schiele F, Ducrocq G, Coste P, Blanchard D, Brasselet C, Elbaz M, Steg PG, Le Breton H, Bonnefoy-Cudraz E, Montalescot G, Cottin Y, Goldstein P, Ferrières J, Simon T, Danchin N, Investigators F-M. 2016. Factors Associated With Infarct-Related Artery Patency Before Primary Percutaneous Coronary Intervention for ST-Elevation Myocardial Infarction (from the FAST-MI 2010 Registry). The American Journal of Cardiology 117:17–21.
1.
Bangalore S, Fayyad R, Kastelein JJ, Laskey R, Amarenco P, DeMicco DA, Waters DD. 2016. 2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis? The American Journal of Medicine 129:384–391.
1.
Blin P, Philippe F, Bouée S, Laurendeau C, Torreton E, Gourmelin J, Leproust S, Levy-Bachelot L, Steg PG. 2016. Outcomes following acute hospitalised myocardial infarction in France: An insurance claims database analysis. International Journal of Cardiology 219:387–393.
1.
Brun A, Rangé H, Prouvost B, Meilhac O, Mazighi M, Amarenco P, Lesèche G, Bouchard P, Michel J-B. 2016. Intraplaque hemorrhage, a potential consequence of periodontal bacteria gathering in human carotid atherothrombosis. Bulletin Du Groupement International Pour La Recherche Scientifique En Stomatologie & Odontologie 53:e11.
1.
Bui AH, Cannon CP, Steg PG, Storey RF, Husted S, Guo J, Im K, James SK, Michelson EL, Himmelmann A, Held C, Varenhorst C, Wallentin L, Scirica BM. 2016. Relationship Between Early and Late Nonsustained Ventricular Tachycardia and Cardiovascular Death in Patients With Acute Coronary Syndrome in the Platelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation Arrhythmia and Electrophysiology 9:e002951.
1.
Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, Kuhls S, van Eickels M, Turpie AGG, Investigators X. 2016. XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. European Heart Journal 37:1145–1153.
1.
Chiang C-E, Naditch-Brûlé L, Brette S, Silva-Cardoso J, Gamra H, Murin J, Zharinov OJ, Steg PG. 2016. Atrial Fibrillation Management Strategies in Routine Clinical Practice: Insights from the International RealiseAF Survey. PloS One 11:e0147536.
1.
Coleman CI, Haas S, Turpie AGG, Kuhls S, Hess S, Evers T, Amarenco P, Kirchhof P, Camm AJ, Investigators X. 2016. Impact of Switching From a Vitamin K Antagonist to Rivaroxaban on Satisfaction With Anticoagulation Therapy: The XANTUS-ACTS Substudy. Clinical Cardiology 39:565–569.
1.
Dangas GD, Schoos MM, Steg PG, Mehran R, Clemmensen P, van ’t Hof A, Prats J, Bernstein D, Deliargyris EN, Stone GW. 2016. Early Stent Thrombosis and Mortality After Primary Percutaneous Coronary Intervention in ST-Segment-Elevation Myocardial Infarction: A Patient-Level Analysis of 2 Randomized Trials. Circulation Cardiovascular Interventions 9:e003272.
1.
Dossier C, Lapidus N, Bayer F, Sellier-Leclerc A-L, Boyer O, de Pontual L, May A, Nathanson S, Orzechowski C, Simon T, Carrat F, Deschênes G. 2016. Epidemiology of idiopathic nephrotic syndrome in children: endemic or epidemic? Pediatric Nephrology (Berlin, Germany) 31:2299–2308.
1.
Ducrocq G, Steg PG, Van’t Hof A, Zeymer U, Mehran R, Hamm CW, Bernstein D, Prats J, Deliargyris EN, Stone GW. 2016. Utility of post-procedural anticoagulation after primary PCI for STEMI: insights from a pooled analysis of the HORIZONS-AMI and EUROMAX trials. European Heart Journal Acute Cardiovascular Care.
1.
Giannitsis E, Wallentin L, James SK, Bertilsson M, Siegbahn A, Storey RF, Husted S, Cannon CP, Armstrong PW, Steg PG, Katus HA, investigators P. 2016. Outcomes after planned invasive or conservative treatment strategy in patients with non-ST-elevation acute coronary syndrome and a normal value of high sensitivity troponin at randomisation: A Platelet Inhibition and Patient Outcomes (PLATO) trial biomarker substudy. European Heart Journal Acute Cardiovascular Care.
1.
Gibson CM, Korjian S, Tricoci P, Daaboul Y, Alexander JH, Steg PG, Lincoff AM, Kastelein JJP, Mehran R, D’Andrea D, Merkely B, Zarebinski M, Ophius TO, Harrington RA. 2016. Rationale and design of Apo-I Event Reduction in Ischemic Syndromes I (AEGIS-I): A phase 2b, randomized, placebo-controlled, dose-ranging trial to investigate the safety and tolerability of CSL112, a reconstituted, infusible, human apoA-I, after acute myocardial infarction. American Heart Journal 180:22–28.
1.
Gomez I, Ozen G, Deschildre C, Amgoud Y, Boubaya L, Gorenne I, Benyahia C, Roger T, Lesèche G, Galardon E, Topal G, Jacob M-P, Longrois D, Norel X. 2016. Reverse Regulatory Pathway (H2S / PGE2 / MMP) in Human Aortic Aneurysm and Saphenous Vein Varicosity. PloS One 11:e0158421.
1.
Gonzalez-Valcarcel J, Sissani L, Labreuche J, Bousser M-G, Chamorro A, Fisher M, Ford I, Fox KM, Hennerici MG, Mattle HP, Rothwell PM, Steg PG, Vicaut E, Amarenco P, Investigators P. 2016. Paracetamol, Ibuprofen, and Recurrent Major Cardiovascular and Major Bleeding Events in 19 120 Patients With Recent Ischemic Stroke. Stroke 47:1045–1052.
1.
Grodzinsky A, Arnold SV, Wang TY, Sharma P, Gosch K, Jones PG, Bhatt DL, Steg PG, McGuire DK, Cohen DJ, Spertus JA, Chhatriwalla AK, Lind M, Graham G, Kosiborod M. 2016. Bleeding risk following percutaneous coronary intervention in patients with diabetes prescribed dual anti-platelet therapy. American Heart Journal 182:111–118.
1.
Hagström E, James SK, Bertilsson M, Becker RC, Himmelmann A, Husted S, Katus HA, Steg PG, Storey RF, Siegbahn A, Wallentin L, Investigators P. 2016. Growth differentiation factor-15 level predicts major bleeding and cardiovascular events in patients with acute coronary syndromes: results from the PLATO study. European Heart Journal 37:1325–1333.
1.
Hajage D, Tubach F, Steg PG, Bhatt DL, De Rycke Y. 2016. On the use of propensity scores in case of rare exposure. BMC medical research methodology 16:38.
1.
Halvorsen S, Storey RF, Rocca B, Sibbing D, Ten Berg J, Grove EL, Weiss TW, Collet J-P, Andreotti F, Gulba DC, Lip GYH, Husted S, Vilahur G, Morais J, Verheugt FWA, Lanas A, Al-Shahi Salman R, Steg PG, Huber K, Thrombosis ESCWG on. 2016. Management of antithrombotic therapy after bleeding in patients with coronary artery disease and/or atrial fibrillation: expert consensus paper of the European Society of Cardiology Working Group on Thrombosis. European Heart Journal.
1.
Helft G, Steg PG, Le Feuvre C, Georges J-L, Carrie D, Dreyfus X, Furber A, Leclercq F, Eltchaninoff H, Falquier J-F, Henry P, Cattan S, Sebagh L, Michel P-L, Tuambilangana A, Hammoudi N, Boccara F, Cayla G, Douard H, Diallo A, Berman E, Komajda M, Metzger J-P, Vicaut E, Investigators OPtiDATT. 2016. Stopping or continuing clopidogrel 12 months after drug-eluting stent placement: the OPTIDUAL randomized trial. European Heart Journal 37:365–374.
1.
Johansson Å, Eriksson N, Lindholm D, Varenhorst C, James S, Syvänen A-C, Axelsson T, Siegbahn A, Barratt BJ, Becker RC, Himmelmann A, Katus HA, Steg PG, Storey RF, Wallentin L, Investigators P. 2016. Genome-wide association and Mendelian randomization study of NT-proBNP in patients with acute coronary syndrome. Human Molecular Genetics 25:1447–1456.
1.
Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Evans SR, Held P, Jonasson J, Minematsu K, Molina CA, Wang Y, Wong KSL, Committee SS, Investigators. 2016. Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. The New England Journal of Medicine 375:35–43.
1.
Jolly SS, Cairns JA, Yusuf S, Rokoss MJ, Gao P, Meeks B, Kedev S, Stankovic G, Moreno R, Gershlick A, Chowdhary S, Lavi S, Niemela K, Bernat I, Cantor WJ, Cheema AN, Steg PG, Welsh RC, Sheth T, Bertrand OF, Avezum A, Bhindi R, Natarajan MK, Horak D, Leung RCM, Kassam S, Rao SV, El-Omar M, Mehta SR, Velianou JL, Pancholy S, Džavík V, Investigators T. 2016. Outcomes after thrombus aspiration for ST elevation myocardial infarction: 1-year follow-up of the prospective randomised TOTAL trial. Lancet (London, England) 387:127–135.
1.
Kaasenbrood L, Boekholdt SM, van der Graaf Y, Ray KK, Peters RJG, Kastelein JJP, Amarenco P, LaRosa JC, Cramer MJM, Westerink J, Kappelle LJ, de Borst GJ, Visseren FLJ. 2016. Distribution of Estimated 10-Year Risk of Recurrent Vascular Events and Residual Risk in a Secondary Prevention Population. Circulation 134:1419–1429.
1.
Kittelson JM, Steg PG, Halperin JL, Goldenberg NA, Schulman S, Spyropoulos AC, Kessler CM, Turpie AGG, Cutler NR, Hiatt WR, Antithrombotic Trials L, Steering G. 2016. Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation. Thrombosis and Haemostasis 116:544–553.
1.
Komajda M, Weidinger F, Kerneis M, Cosentino F, Cremonesi A, Ferrari R, Kownator S, Steg PG, Tavazzi L, Valgimigli M, Szwed H, Majda W, Olivari Z, Van Belle E, Shlyakhto EV, Mintale I, Slapikas R, Rittger H, Mendes M, Tsioufis C, Balanescu S, Laroche C, Maggioni AP. 2016. EURObservational Research Programme: the Chronic Ischaemic Cardiovascular Disease Registry: Pilot phase (CICD-PILOT). European Heart Journal 37:152–160.
1.
Leblanc J, Rousseau A, Hejblum G, Durand-Zaleski I, de Truchis P, Lert F, Costagliola D, Simon T, Crémieux A-C. 2016. The impact of nurse-driven targeted HIV screening in 8 emergency departments: study protocol for the DICI-VIH cluster-randomized two-period crossover trial. BMC infectious diseases 16:51.
1.
Lefevre JH, Mineur L, Kotti S, Rullier E, Rouanet P, de Chaisemartin C, Meunier B, Mehrdad J, Cotte E, Desrame J, Karoui M, Benoist S, Kirzin S, Berger A, Panis Y, Piessen G, Saudemont A, Prudhomme M, Peschaud F, Dubois A, Loriau J, Tuech J-J, Meurette G, Lupinacci R, Goasgen N, Parc Y, Simon T, Tiret E. 2016. Effect of Interval (7 or 11 weeks) Between Neoadjuvant Radiochemotherapy and Surgery on Complete Pathologic Response in Rectal Cancer: A Multicenter, Randomized, Controlled Trial (GRECCAR-6). Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology.
1.
Mas J-L, Derumeaux G, Amarenco P, Arquizan C, Aubry P, Barthelet M, Bertrand B, Brochet E, Cabanes L, Donal E, Dubois-Randé J-L, Durand-Zaleski I, Ernande L, Finet G, Fraisse A, Giroud M, Guérin P, Habib G, Juliard J-M, Leys D, Lièvre M, Lusson J-R, Marcon F, Michel P, Moulin T, Mounier-Vehier F, Pierard L, Piot C, Rey C, Rodier G, Roudaut R, Schleich J-M, Teiger E, Turc G, Vuillier F, Weimar C, Woimant F, Chatellier G, investigators C. 2016. close: Closure of patent foramen ovale, oral anticoagulants or antiplatelet therapy to prevent stroke recurrence: Study design. International Journal of Stroke: Official Journal of the International Stroke Society 11:724–732.
1.
Mega JL, Close SL, Wiviott SD, Man M, Duvvuru S, Walker JR, Sundseth SS, Collet J-P, Delaney JT, Hulot J-S, Murphy SA, Paré G, Price MJ, Sibbing D, Simon T, Trenk D, Antman EM, Sabatine MS. 2016. PON1 Q192R genetic variant and response to clopidogrel and prasugrel: pharmacokinetics, pharmacodynamics, and a meta-analysis of clinical outcomes. Journal of Thrombosis and Thrombolysis 41:374–383.
1.
Olivot J-M, Sissani L, Meseguer E, Inoue M, Labreuche J, Mlynash M, Amarenco P, Mazighi M. 2016. Impact of Initial Diffusion-Weighted Imaging Lesion Growth Rate on the Success of Endovascular Reperfusion Therapy. Stroke 47:2305–2310.
1.
Ortiz-Munoz G, Couret D, Lapergue B, Bruckert E, Meseguer E, Amarenco P, Meilhac O. 2016. Dysfunctional HDL in acute stroke. Atherosclerosis 253:75–80.
1.
Pico F, Labreuche J, Hauw J-J, Seilhean D, Duyckaerts C, Amarenco P. 2016. Coronary and Basilar Artery Ectasia Are Associated: Results From an Autopsy Case-Control Study. Stroke 47:224–227.
1.
Pico F, Rosso C, Meseguer E, Chadenat M-L, Cattenoy A, Aegerter P, Deltour S, Yeung J, Hosseini H, Lambert Y, Smadja D, Samson Y, Amarenco P. 2016. A multicenter, randomized trial on neuroprotection with remote ischemic per-conditioning during acute ischemic stroke: the REmote iSchemic Conditioning in acUtE BRAin INfarction study protocol. International Journal of Stroke: Official Journal of the International Stroke Society 11:938–943.
1.
Pouche M, Ruidavets J-B, Ferrières J, Iliou M-C, Douard H, Lorgis L, Carrié D, Brunel P, Simon T, Bataille V, Danchin N. 2016. Cardiac rehabilitation and 5-year mortality after acute coronary syndromes: The 2005 French FAST-MI study. Archives of Cardiovascular Diseases 109:178–187.
1.
Povsic TJ, Roe MT, Ohman EM, Steg PG, James S, Plotnikov A, Mundl H, Welsh R, Bode C, Gibson CM. 2016. A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study. American Heart Journal 174:120–128.
1.
Puymirat E, Lamhaut L, Bonnet N, Aissaoui N, Henry P, Cayla G, Cattan S, Steg G, Mock L, Ducrocq G, Goldstein P, Schiele F, Bonnefoy-Cudraz E, Simon T, Danchin N. 2016. Correlates of pre-hospital morphine use in ST-elevation myocardial infarction patients and its association with in-hospital outcomes and long-term mortality: the FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) programme. European Heart Journal 37:1063–1071.
1.
Puymirat E, Riant E, Aissoui N, Soria A, Ducrocq G, Coste P, Cottin Y, Aupetit JF, Bonnefoy E, Blanchard D, Cattan S, Steg G, Schiele F, Ferrières J, Juillière Y, Simon T, Danchin N. 2016. β blockers and mortality after myocardial infarction in patients without heart failure: multicentre prospective cohort study. BMJ (Clinical research ed) 354:i4801.
1.
Puymirat E, Schiele F, Zeller M, Jacquemin L, Leclercq F, Marcaggi X, Ferrières J, Simon T, Danchin N, investigators F-M. 2016. Do randomized clinical trial selection criteria reflect levels of risk as observed in a general population of acute myocardial infarction survivors? The PEGASUS trial in the light of the FAST-MI 2005 registry. International Journal of Cardiology 223:604–610.
1.
Raskob GE, Spyropoulos AC, Zrubek J, Ageno W, Albers G, Elliott CG, Halperin J, Haskell L, Hiatt WR, Maynard GA, Peters G, Spiro T, Steg PG, Suh EY, Weitz JI. 2016. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications. Thrombosis and Haemostasis 115:1240–1248.
1.
Ridker PM, Amarenco P, Brunell R, Glynn RJ, Jukema JW, Kastelein JJP, Koenig W, Nissen S, Revkin J, Santos RD, Schwartz PF, Yunis C, Tardif J-C, Studies of PI, the Reduction of vascular Events I. 2016. Evaluating bococizumab, a monoclonal antibody to PCSK9, on lipid levels and clinical events in broad patient groups with and without prior cardiovascular events: Rationale and design of the Studies of PCSK9 Inhibition and the Reduction of vascular Events (SPIRE) Lipid Lowering and SPIRE Cardiovascular Outcomes Trials. American Heart Journal 178:135–144.
1.
Riegger J, Byrne RA, Joner M, Chandraratne S, Gershlick AH, Ten Berg JM, Adriaenssens T, Guagliumi G, Godschalk TC, Neumann F-J, Trenk D, Feldman LJ, Steg PG, Desmet W, Alfonso F, Goodall AH, Wojdyla R, Dudek D, Philippi V, Opinaldo S, Titova A, Malik N, Cotton J, Jhagroe DA, Heestermans AACM, Sinnaeve P, Vermeersch P, Valina C, Schulz C, Kastrati A, Massberg S, Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort I. 2016. Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortium. European Heart Journal 37:1538–1549.
1.
Schiele F, Puymirat E, Bonello L, Meneveau N, Collet J-P, Motreff P, Ravan R, Leclercq F, Ennezat P-V, Ferrières J, Simon T, Danchin N. 2016. Switching between thienopyridines in patients with acute myocardial infarction and quality of care. Open Heart 3:e000384.
1.
Steg PG, Ducrocq G. 2016. Future of the Prevention and Treatment of Coronary Artery Disease. Circulation Journal: Official Journal of the Japanese Circulation Society 80:1067–1072.
1.
Steg PG, Roussel R. 2016. Randomized Trials to Evaluate Cardiovascular Safety of Antihyperglycemic Medications: A Worthwhile Effort? Circulation 134:571–573.
1.
Steg PG, Serruys PW, Abdelghani M, Wijns W. 2016. The year in cardiology 2015: coronary intervention. European Heart Journal 37:335–343.
1.
Storey RF, Angiolillo DJ, Bonaca MP, Thomas MR, Judge HM, Rollini F, Franchi F, Ahsan AJ, Bhatt DL, Kuder JF, Steg PG, Cohen M, Muthusamy R, Braunwald E, Sabatine MS. 2016. Platelet Inhibition With Ticagrelor 60 mg Versus 90 mg Twice Daily in the PEGASUS-TIMI 54 Trial. Journal of the American College of Cardiology 67:1145–1154.
1.
Tendera M, Chassany O, Ferrari R, Ford I, Steg PG, Tardif J-C, Fox K, Investigators S. 2016. Quality of Life With Ivabradine in Patients With Angina Pectoris: The Study Assessing the Morbidity-Mortality Benefits of the If Inhibitor Ivabradine in Patients With Coronary Artery Disease Quality of Life Substudy. Circulation Cardiovascular Quality and Outcomes 9:31–38.
1.
Vidal-Petiot E, Ford I, Greenlaw N, Ferrari R, Fox KM, Tardif J-C, Tendera M, Tavazzi L, Bhatt DL, Steg PG, Investigators C. 2016. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. Lancet (London, England) 388:2142–2152.
1.
Vranckx P, Valgimigli M, Windecker S, Steg PG, Hamm C, Jüni P, Garcia-Garcia HM, van Es GA, Serruys PW. 2016. Long-term ticagrelor monotherapy versus standard dual antiplatelet therapy followed by aspirin monotherapy in patients undergoing biolimus-eluting stent implantation: rationale and design of the GLOBAL LEADERS trial. EuroIntervention: Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 12:1239–1245.
1.
Wallentin L, Held C, Armstrong PW, Cannon CP, Davies RY, Granger CB, Hagström E, Harrington RA, Hochman JS, Koenig W, Krug-Gourley S, Mohler ER, Siegbahn A, Tarka E, Steg PG, Stewart RAH, Weiss R, Östlund O, White HD, Investigators S. 2016. Lipoprotein-Associated Phospholipase A2 Activity Is a Marker of Risk But Not a Useful Target for Treatment in Patients With Stable Coronary Heart Disease. Journal of the American Heart Association 5.
1.
Welsh RC, Roe MT, Steg PG, James S, Povsic TJ, Bode C, Gibson CM, Ohman EM. 2016. A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease. American Heart Journal 181:92–100.
1.
Yayehd K, N’da NW, Belle L, Bataille V, Hanssen M, Leddet P, Aupetit J-F, Commeau P, Filippi E, Georges J-L, Albert F, Rangé G, Meimoun P, Marcaggi X, Baleynaud S, Nallet O, Dibie A, Barnay C, Jouve B, Legrand M, Cattan S, Mulak G, Simon T, Danchin N, Dujardin J-J, investigators O. 2016. Management of Takotsubo cardiomyopathy in non-academic hospitals in France: The Observational French SyndromEs of TakoTsubo (OFSETT) study. Archives of Cardiovascular Diseases 109:4–12.
1.
Yeh RW, Secemsky EA, Kereiakes DJ, Normand S-LT, Gershlick AH, Cohen DJ, Spertus JA, Steg PG, Cutlip DE, Rinaldi MJ, Camenzind E, Wijns W, Apruzzese PK, Song Y, Massaro JM, Mauri L, Investigators DS. 2016. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention. JAMA 315:1735–1749.
1.
Yu J, Baber U, Mastoris I, Dangas G, Sartori S, Steg PG, Cohen DJ, Giustino G, Chandrasekhar J, Ariti C, Witzenbichler B, Henry TD, Kini AS, Krucoff MW, Gibson CM, Chieffo A, Moliterno DJ, Colombo A, Pocock S, Mehran R. 2016. Sex-Based Differences in Cessation of Dual-Antiplatelet Therapy Following Percutaneous Coronary Intervention With Stents. JACC Cardiovascular interventions 9:1461–1469.
1.
Zeller M, Labalette-Bart M, Juliard J-M, Potier L, Feldman LJ, Steg PG, Cottin Y, Roussel R. 2016. Metformin and contrast-induced acute kidney injury in diabetic patients treated with primary percutaneous coronary intervention for ST segment elevation myocardial infarction: Amulticenter study. International Journal of Cardiology 220:137–142.

2015

1.
Alexander SP, Kelly E, Marrion N, Peters JA, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Southan C, Buneman OP, Catterall WA, Cidlowski JA, Davenport AP, Fabbro D, Fan G, McGrath JC, Spedding M, Davies JA, Collaborators C. 2015. The Concise Guide to PHARMACOLOGY 2015/16: Overview. British Journal of Pharmacology 172:5729–5743.
1.
Alexopoulos D, Bhatt DL, Hamm CW, Steg PG, Stone GW. 2015. Early P2Y12 inhibition in ST-segment elevation myocardial infarction: Bridging the gap. American Heart Journal 170:3–12.
1.
Benyahia C, Ozen G, Orie N, Ledwozyw A, Louedec L, Li F, Senbel AM, Silverstein A, Danel C, Longrois D, Clapp LH, Norel X, Topal G. 2015. Ex vivo relaxations of pulmonary arteries induced by prostacyclin mimetics are highly dependent of the precontractile agents. Prostaglandins & Other Lipid Mediators 121:46–52.
1.
Bonaca MP, Bhatt DL, Cohen M, Steg PG, Storey RF, Jensen EC, Magnani G, Bansilal S, Fish MP, Im K, Bengtsson O, Oude Ophuis T, Budaj A, Theroux P, Ruda M, Hamm C, Goto S, Spinar J, Nicolau JC, Kiss RG, Murphy SA, Wiviott SD, Held P, Braunwald E, Sabatine MS, Committee P-TS, Investigators. 2015. Long-term use of ticagrelor in patients with prior myocardial infarction. The New England Journal of Medicine 372:1791–1800.
1.
Boufenzer A, Lemarié J, Simon T, Derive M, Bouazza Y, Tran N, Maskali F, Groubatch F, Bonnin P, Bastien C, Bruneval P, Marie P-Y, Cohen R, Danchin N, Silvestre J-S, Ait-Oufella H, Gibot S. 2015. TREM-1 Mediates Inflammatory Injury and Cardiac Remodeling Following Myocardial Infarction. Circulation Research 116:1772–1782.
1.
Bouleti C, Mathivet T, Serfaty J-M, Vignolles N, Berland E, Monnot C, Cluzel P, Steg PG, Montalescot G, Germain S. 2015. Angiopoietin-like 4 serum levels on admission for acute myocardial infarction are associated with no-reflow. International Journal of Cardiology 187:511–516.
1.
Bourron O, Le Bouc Y, Berard L, Kotti S, Brunel N, Ritz B, Leclercq F, Tabone X, Drouet E, Mulak G, Danchin N, Simon T. 2015. Impact of age-adjusted insulin-like growth factor 1 on major cardiovascular events after acute myocardial infarction: results from the fast-MI registry. The Journal of Clinical Endocrinology and Metabolism 100:1879–1886.
1.
Clemmensen P, Wiberg S, Van’t Hof A, Deliargyris EN, Coste P, Ten Berg J, Cavallini C, Hamon M, Dudek D, Zeymer U, Tabone X, Kristensen SD, Bernstein D, Anthopoulos P, Prats J, Steg PG. 2015. Acute stent thrombosis after primary percutaneous coronary intervention: insights from the EUROMAX trial (European Ambulance Acute Coronary Syndrome Angiography). JACC Cardiovascular interventions 8:214–220.
1.
Cung T-T, Morel O, Cayla G, Rioufol G, Garcia-Dorado D, Angoulvant D, Bonnefoy-Cudraz E, Guérin P, Elbaz M, Delarche N, Coste P, Vanzetto G, Metge M, Aupetit J-F, Jouve B, Motreff P, Tron C, Labeque J-N, Steg PG, Cottin Y, Range G, Clerc J, Claeys MJ, Coussement P, Prunier F, Moulin F, Roth O, Belle L, Dubois P, Barragan P, Gilard M, Piot C, Colin P, De Poli F, Morice M-C, Ider O, Dubois-Randé J-L, Unterseeh T, Le Breton H, Béard T, Blanchard D, Grollier G, Malquarti V, Staat P, Sudre A, Elmer E, Hansson MJ, Bergerot C, Boussaha I, Jossan C, Derumeaux G, Mewton N, Ovize M. 2015. Cyclosporine before PCI in Patients with Acute Myocardial Infarction. The New England Journal of Medicine 373:1021–1031.
1.
Degrell P, Sorbets E, Feldman LJ, Steg PG, Ducrocq G. 2015. Screening for coronary artery disease in asymptomatic individuals: Why and how? Archives of Cardiovascular Diseases 108:675–682.
1.
Desilles J-P, Loyau S, Syvannarath V, Gonzalez-Valcarcel J, Cantier M, Louedec L, Lapergue B, Amarenco P, Ajzenberg N, Jandrot-Perrus M, Michel J-B, Ho-Tin-Noe B, Mazighi M. 2015. Alteplase Reduces Downstream Microvascular Thrombosis and Improves the Benefit of Large Artery Recanalization in Stroke. Stroke 46:3241–3248.
1.
Donataccio MP, Puymirat E, Parapid B, Steg PG, Eltchaninoff H, Weber S, Ferrari E, Vilarem D, Charpentier S, Manzo-Silberman S, Ferrières J, Danchin N, Simon T. 2015. In-hospital outcomes and long-term mortality according to sex and management strategy in acute myocardial infarction. Insights from the French ST-elevation and non-ST-elevation Myocardial Infarction (FAST-MI) 2005 Registry. International Journal of Cardiology 201:265–270.
1.
Ducrocq G, Jolly S, Mehta SR, Rao SV, Patel T, Moreno R, Gao P, Steg PG. 2015. Activated clotting time and outcomes during percutaneous coronary intervention for non-ST-segment-elevation myocardial infarction: insights from the FUTURA/OASIS-8 Trial. Circulation Cardiovascular Interventions 8.
1.
Ducrocq G, Puymirat E, Steg PG, Henry P, Martelet M, Karam C, Schiele F, Simon T, Danchin N. 2015. Blood transfusion, bleeding, anemia, and survival in patients with acute myocardial infarction: FAST-MI registry. American Heart Journal 170:726–734.e2.
1.
Ducrocq G, Schulte PJ, Becker RC, Cannon CP, Harrington RA, Held C, Himmelmann A, Lassila R, Storey RF, Sorbets E, Wallentin L, Steg PG. 2015. Association of spontaneous and procedure-related bleeds with short- and long-term mortality after acute coronary syndromes: an analysis from the PLATO trial. EuroIntervention: Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 11:737–745.
1.
Ducrocq G, Steg PG. 2015. Treating coronary artery disease in patients with a history of cerebrovascular disease. Archives of Cardiovascular Diseases 108:606–611.
1.
Elmariah S, Mauri L, Doros G, Galper BZ, O’Neill KE, Steg PG, Kereiakes DJ, Yeh RW. 2015. Extended duration dual antiplatelet therapy and mortality: a systematic review and meta-analysis. Lancet (London, England) 385:792–798.
1.
Erglis A, Mintale I, Latkovskis G, Balode I, Jegere S, Bajare I, Rozenbergs A, Greenlaw N, Ferrari R, Steg PG, investigators C registry. 2015. Management of coronary artery disease patients in Latvia compared with practice in Central-Eastern Europe and globally: analysis of the CLARIFY registry. Medicina (Kaunas, Lithuania) 51:240–246.
1.
Fox K, Ford I, Steg PG, Tardif J-C, Tendera M, Ferrari R, investigators S. 2015. Bradycardia and atrial fibrillation in patients with stable coronary artery disease treated with ivabradine: an analysis from the SIGNIFY study. European Heart Journal 36:3291–3296.
1.
Freund Y, Rousseau A, Berard L, Goulet H, Ray P, Bloom B, Simon T, Riou B. 2015. Cross-checking to reduce adverse events resulting from medical errors in the emergency department: study protocol of the CHARMED cluster randomized study. BMC emergency medicine 15:21.
1.
Freund Y, Rousseau A, Guyot-Rousseau F, Claessens Y-E, Hugli O, Sanchez O, Simon T, Riou B. 2015. PERC rule to exclude the diagnosis of pulmonary embolism in emergency low-risk patients: study protocol for the PROPER randomized controlled study. Trials 16:537.
1.
Gershlick AH, Westerhout CM, Armstrong PW, Huber K, Halvorsen S, Steg PG, Ostojic M, Goldstein P, Carvalho AC, Van de Werf F, Wilcox RG. 2015. Impact of a pharmacoinvasive strategy when delays to primary PCI are prolonged. Heart (British Cardiac Society) 101:692–698.
1.
Giustino G, Baber U, Stefanini GG, Aquino M, Stone GW, Sartori S, Steg PG, Wijns W, Smits PC, Jeger RV, Leon MB, Windecker S, Serruys PW, Morice M-C, Camenzind E, Weisz G, Kandzari D, Dangas GD, Mastoris I, Von Birgelen C, Galatius S, Kimura T, Mikhail G, Itchhaporia D, Mehta L, Ortega R, Kim H-S, Valgimigli M, Kastrati A, Chieffo A, Mehran R. 2015. Impact of Clinical Presentation (Stable Angina Pectoris vs Unstable Angina Pectoris or Non-ST-Elevation Myocardial Infarction vs ST-Elevation Myocardial Infarction) on Long-Term Outcomes in Women Undergoing Percutaneous Coronary Intervention With Drug-Eluting Stents. The American Journal of Cardiology 116:845–852.
1.
Goumard C, Cachanado M, Herrero A, Rousseau G, Dondero F, Compagnon P, Boleslawski E, Mabrut JY, Salamé E, Soubrane O, Simon T, Scatton O. 2015. Biliary reconstruction with or without an intraductal removable stent in liver transplantation: study protocol for a randomized controlled trial. Trials 16:598.
1.
Hamill V, Ford I, Fox K, Böhm M, Borer JS, Ferrari R, Komajda M, Steg PG, Tavazzi L, Tendera M, Swedberg K. 2015. Repeated heart rate measurement and cardiovascular outcomes in left ventricular systolic dysfunction. The American Journal of Medicine 128:1102–1108.e6.
1.
Hamon M, Coste P, Van’t Hof A, Ten Berg J, Clemmensen P, Tabone X, Benamer H, Kristensen SD, Cavallini C, Marzocchi A, Hamm C, Kanic V, Bernstein D, Anthopoulos P, Deliargyris EN, Steg PG. 2015. Impact of arterial access site on outcomes after primary percutaneous coronary intervention: prespecified subgroup analysis from the EUROMAX trial. Circulation Cardiovascular Interventions 8:e002049.
1.
Johansson Å, Eriksson N, Becker RC, Storey RF, Himmelmann A, Hagström E, Varenhorst C, Axelsson T, Barratt BJ, James SK, Katus HA, Steg PG, Syvänen A-C, Wallentin L, Siegbahn A, Investigators P. 2015. NLRC4 Inflammasome Is an Important Regulator of Interleukin-18 Levels in Patients With Acute Coronary Syndromes: Genome-Wide Association Study in the PLATelet inhibition and patient Outcomes Trial (PLATO). Circulation Cardiovascular Genetics 8:498–506.
1.
Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Held P, Jonasson J, Minematsu K, Molina CA, Wong LKS. 2015. Acute Stroke or Transient Ischemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes (SOCRATES) trial: rationale and design. International Journal of Stroke: Official Journal of the International Stroke Society 10:1304–1308.
1.
Jolly SS, Cairns JA, Yusuf S, Meeks B, Pogue J, Rokoss MJ, Kedev S, Thabane L, Stankovic G, Moreno R, Gershlick A, Chowdhary S, Lavi S, Niemelä K, Steg PG, Bernat I, Xu Y, Cantor WJ, Overgaard CB, Naber CK, Cheema AN, Welsh RC, Bertrand OF, Avezum A, Bhindi R, Pancholy S, Rao SV, Natarajan MK, ten Berg JM, Shestakovska O, Gao P, Widimsky P, Džavík V, Investigators T. 2015. Randomized trial of primary PCI with or without routine manual thrombectomy. The New England Journal of Medicine 372:1389–1398.
1.
Kholaif N, Zheng Y, Jagasia P, Himmelmann A, James SK, Steg PG, Storey RF, Westerhout CM, Armstrong PW. 2015. Baseline Q waves and time from symptom onset to ST-segment elevation myocardial infarction: insights from PLATO on the influence of sex. The American Journal of Medicine 128:914.e11–19.
1.
Leblanc J, Burnet E, D’Almeida KW, Lert F, Simon T, Crémieux A-C. 2015. The role of nurses in HIV screening in health care facilities: A systematic review. International Journal of Nursing Studies 52:1495–1513.
1.
Mawhin M-A, Tilly P, Fabre J-E. 2015. The receptor EP3 to PGE2: A rational target to prevent atherothrombosis without inducing bleeding. Prostaglandins & Other Lipid Mediators 121:4–16.
1.
Mega JL, Simon T. 2015. Pharmacology of antithrombotic drugs: an assessment of oral antiplatelet and anticoagulant treatments. Lancet (London, England) 386:281–291.
1.
Meseguer E, Labreuche J, Guidoux C, Lavallée PC, Cabrejo L, Sirimarco G, Valcarcel JG, Klein IF, Amarenco P, Mazighi M. 2015. Outcomes after stroke thrombolysis according to prior antiplatelet use. International Journal of Stroke: Official Journal of the International Stroke Society 10:163–169.
1.
Metghalchi S, Ponnuswamy P, Simon T, Haddad Y, Laurans L, Clément M, Dalloz M, Romain M, Esposito B, Koropoulis V, Lamas B, Paul J-L, Cottin Y, Kotti S, Bruneval P, Callebert J, den Ruijter H, Launay J-M, Danchin N, Sokol H, Tedgui A, Taleb S, Mallat Z. 2015. Indoleamine 2,3-Dioxygenase Fine-Tunes Immune Homeostasis in Atherosclerosis and Colitis through Repression of Interleukin-10 Production. Cell Metabolism 22:460–471.
1.
Nighoghossian N, Berthezène Y, Mechtouff L, Derex L, Cho TH, Ritzenthaler T, Rheims S, Chauveau F, Béjot Y, Jacquin A, Giroud M, Ricolfi F, Philippeau F, Lamy C, Turc G, Bodiguel E, Domigo V, Guiraud V, Mas J-L, Oppenheim C, Amarenco P, Cakmak S, Sevin-Allouet M, Guillon B, Desal H, Hosseini H, Sibon I, Mahagne M-H, Ong E, Mewton N, Ovize M. 2015. Cyclosporine in acute ischemic stroke. Neurology 84:2216–2223.
1.
Ozen G, Daci A, Norel X, Topal G. 2015. Human perivascular adipose tissue dysfunction as a cause of vascular disease: Focus on vascular tone and wall remodeling. European Journal of Pharmacology 766:16–24.
1.
Pico F, Labreuche J, Amarenco P. 2015. Pathophysiology, presentation, prognosis, and management of intracranial arterial dolichoectasia. The Lancet Neurology 14:833–845.
1.
Potier L, Roussel R, Labreuche J, Marre M, Cacoub P, Röther J, Wilson PWF, Goto S, Bhatt DL, Steg PG, Investigators R. 2015. Interaction between diabetes and a high ankle-brachial index on mortality risk. European Journal of Preventive Cardiology 22:615–621.
1.
Preiss D, Campbell RT, Murray HM, Ford I, Packard CJ, Sattar N, Rahimi K, Colhoun HM, Waters DD, LaRosa JC, Amarenco P, Pedersen TR, Tikkanen MJ, Koren MJ, Poulter NR, Sever PS, Ridker PM, MacFadyen JG, Solomon SD, Davis BR, Simpson LM, Nakamura H, Mizuno K, Marfisi RM, Marchioli R, Tognoni G, Athyros VG, Ray KK, Gotto AM, Clearfield MB, Downs JR, McMurray JJ. 2015. The effect of statin therapy on heart failure events: a collaborative meta-analysis of unpublished data from major randomized trials. European Heart Journal 36:1536–1546.
1.
Puymirat E, Schiele F, Ennezat P-V, Coste P, Collet J-P, Bonnefoy-Cudraz E, Roul G, Richard P, Simon T, Danchin N. 2015. Impact of fondaparinux versus enoxaparin on in-hospital bleeding and 1-year death in non-ST-segment elevation myocardial infarction. FAST-MI (French Registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction) 2010. European Heart Journal Acute Cardiovascular Care 4:211–219.
1.
Puymirat E, Teixeira N, Simon T, Steg PG, Schiele F, Lamblin N, Probst V, Juillière Y, Ferrières J, Danchin N, investigators F-M. 2015. Patient education after acute myocardial infarction: cardiologists should adapt their message–French registry of acute ST-elevation or non-ST-elevation myocardial infarction 2010 registry. Journal of Cardiovascular Medicine (Hagerstown, Md) 16:761–767.
1.
Rio B, Chevret S, Vigouroux S, Chevallier P, Fürst S, Sirvent A, Bay J-O, Socié G, Ceballos P, Huynh A, Cornillon J, Françoise S, Legrand F, Yakoub-Agha I, Michel G, Maillard N, Margueritte G, Maury S, Uzunov M, Bulabois CE, Michallet M, Clement L, Dauriac C, Bilger K, Gluckman E, Ruggeri A, Buzyn A, Nguyen S, Simon T, Milpied N, Rocha V, Société Française de Greffe de Moelle et de Thérapie C, Eurocord. 2015. Decreased nonrelapse mortality after unrelated cord blood transplantation for acute myeloid leukemia using reduced-intensity conditioning: a prospective phase II multicenter trial. Biology of Blood and Marrow Transplantation: Journal of the American Society for Blood and Marrow Transplantation 21:445–453.
1.
Schiele F, Puymirat E, Bonello L, Dentan G, Meneveau N, Collet J-P, Motreff P, Ravan R, Leclercq F, Ennezat P-V, Ferrières J, Berard L, Simon T, Danchin N. 2015. Impact of prolonged dual antiplatelet therapy after acute myocardial infarction on 5-year mortality in the FAST-MI 2005 registry. International Journal of Cardiology 187:354–360.
1.
Secemsky EA, Matteau A, Yeh RW, Steg PG, Camenzind E, Wijns W, McFadden E, Mauri L, Investigators PT. 2015. Comparison of Short- and Long-Term Cardiac Mortality in Early Versus Late Stent Thrombosis (from Pooled PROTECT Trials). The American Journal of Cardiology 115:1678–1684.
1.
Steg PG, van’t Hof AW, Zeymer U, Goldstein P. 2015. Bivalirudin versus heparin use for patients undergoing PPCI. Lancet (London, England) 385:2043–2044.
1.
Stone GW, Mehran R, Goldstein P, Witzenbichler B, Van’t Hof A, Guagliumi G, Hamm CW, Généreux P, Clemmensen P, Pocock SJ, Gersh BJ, Bernstein D, Deliargyris EN, Steg PG. 2015. Bivalirudin versus heparin with or without glycoprotein IIb/IIIa inhibitors in patients with STEMI undergoing primary percutaneous coronary intervention: pooled patient-level analysis from the HORIZONS-AMI and EUROMAX trials. Journal of the American College of Cardiology 65:27–38.
1.
Stone GW, Mehran R, Steg PG. 2015. Follow the data: bivalirudin (and not heparin alone) during percutaneous coronary intervention provides the best clinical outcomes. JACC Cardiovascular interventions 8:225–227.
1.
Swerdlow DI, Preiss D, Kuchenbaecker KB, Holmes MV, Engmann JEL, Shah T, Sofat R, Stender S, Johnson PCD, Scott RA, Leusink M, Verweij N, Sharp SJ, Guo Y, Giambartolomei C, Chung C, Peasey A, Amuzu A, Li K, Palmen J, Howard P, Cooper JA, Drenos F, Li YR, Lowe G, Gallacher J, Stewart MCW, Tzoulaki I, Buxbaum SG, van der A DL, Forouhi NG, Onland-Moret NC, van der Schouw YT, Schnabel RB, Hubacek JA, Kubinova R, Baceviciene M, Tamosiunas A, Pajak A, Topor-Madry R, Stepaniak U, Malyutina S, Baldassarre D, Sennblad B, Tremoli E, de Faire U, Veglia F, Ford I, Jukema JW, Westendorp RGJ, de Borst GJ, de Jong PA, Algra A, Spiering W, Maitland-van der Zee AH, Klungel OH, de Boer A, Doevendans PA, Eaton CB, Robinson JG, Duggan D, Consortium D, Consortium M, InterAct C, Kjekshus J, Downs JR, Gotto AM, Keech AC, Marchioli R, Tognoni G, Sever PS, Poulter NR, Waters DD, Pedersen TR, Amarenco P, Nakamura H, McMurray JJV, Lewsey JD, Chasman DI, Ridker PM, Maggioni AP, Tavazzi L, Ray KK, Seshasai SRK, Manson JE, Price JF, Whincup PH, Morris RW, Lawlor DA, Smith GD, Ben-Shlomo Y, Schreiner PJ, Fornage M, Siscovick DS, Cushman M, Kumari M, Wareham NJ, Verschuren WMM, Redline S, Patel SR, others. 2015. HMG-coenzyme A reductase inhibition, type 2 diabetes, and bodyweight: evidence from genetic analysis and randomised trials. Lancet (London, England) 385:351–361.
1.
Topal G, Clària J, Norel X, Steinhilber D, Jakobsson P-J, Doğan SU, Bannenberg G. 2015. Editorial. Prostaglandins & Other Lipid Mediators 121:1–3.
1.
Van’t Hof A, Giannini F, Ten Berg J, Tolsma R, Clemmensen P, Bernstein D, Coste P, Goldstein P, Zeymer U, Hamm C, Deliargyris E, Steg PG. 2015. ST-segment resolution with bivalirudin versus heparin and routine glycoprotein IIb/IIIa inhibitors started in the ambulance in ST-segment elevation myocardial infarction patients transported for primary percutaneous coronary intervention: The EUROMAX ST-segment resolution substudy. European Heart Journal Acute Cardiovascular Care.
1.
Vulser H, Wiernik E, Tartour E, Thomas F, Pannier B, Czernichow S, Hanon O, Simon T, Simon J-M, Ducolombier C, Consoli SM, Danchin N, Limosin F, Lemogne C. 2015. Smoking and the Association Between Depressive Symptoms and Absolute Neutrophil Count in the Investigations Préventives et Cliniques Cohort Study. Psychosomatic Medicine 77:1039–1049.
1.
Wiviott SD, Steg PG. 2015. Clinical evidence for oral antiplatelet therapy in acute coronary syndromes. Lancet (London, England) 386:292–302.
1.
Yeh RW, Kereiakes DJ, Steg PG, Windecker S, Rinaldi MJ, Gershlick AH, Cutlip DE, Cohen DJ, Tanguay J-F, Jacobs A, Wiviott SD, Massaro JM, Iancu AC, Mauri L, Investigators DS. 2015. Benefits and Risks of Extended Duration Dual Antiplatelet Therapy After PCI in Patients With and Without Acute Myocardial Infarction. Journal of the American College of Cardiology 65:2211–2221.

2014

1.
Abtan J, Elbez Y, Bhatt DL, Steg PG. 2014. Lack of negative interaction between use of β-blockers and statins on cardiovascular outcomes among patients with or at risk for atherothrombosis. Journal of the American College of Cardiology 64:845–847.
1.
Adlbrecht C, Huber K, Reynolds HR, Carvalho AC, Džavík V, Steg PG, Liu L, Marino P, Pearte CA, Rankin JM, White HD, Lamas GA, Hochman JS. 2014. Effects of timing, location and definition of reinfarction on mortality in patients with totally occluded infarct related arteries late after myocardial infarction. International Journal of Cardiology 174:90–95.
1.
Aissaoui N, Puymirat E, Simon T, Bonnefoy-Cudraz E, Angoulvant D, Schiele F, Benamer H, Quandalle P, Prunier F, Durand E, Berard L, Blanchard D, Danchin N. 2014. Long-term outcome in early survivors of cardiogenic shock at the acute stage of myocardial infarction: a landmark analysis from the French registry of Acute ST-elevation and non-ST-elevation Myocardial Infarction (FAST-MI) Registry. Critical Care (London, England) 18:516.
1.
Alexander JH, Lopes RD, Thomas L, Alings M, Atar D, Aylward P, Goto S, Hanna M, Huber K, Husted S, Lewis BS, McMurray JJV, Pais P, Pouleur H, Steg PG, Verheugt FWA, Wojdyla DM, Granger CB, Wallentin L. 2014. Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from the ARISTOTLE trial. European Heart Journal 35:224–232.
1.
Amarenco P, Abboud H, Labreuche J, Arauz A, Bryer A, Lavados PM, Massaro A, Munoz Collazos M, Steg PG, Yamout BI, Vicaut E, Investigators OR. 2014. Impact of living and socioeconomic characteristics on cardiovascular risk in ischemic stroke patients. International Journal of Stroke: Official Journal of the International Stroke Society 9:1065–1072.
1.
Amarenco P, Callahan A, Campese VM, Goldstein LB, Hennerici MG, Messig M, Sillesen H, Welch KMA, Wilson DJ, Zivin JA. 2014. Effect of high-dose atorvastatin on renal function in subjects with stroke or transient ischemic attack in the SPARCL trial. Stroke 45:2974–2982.
1.
Amarenco P, Davis S, Jones EF, Cohen AA, Heiss W-D, Kaste M, Laouénan C, Young D, Macleod M, Donnan GA, Aortic Arch Related Cerebral Hazard Trial I. 2014. Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques. Stroke 45:1248–1257.
1.
André R, Elbaz M, Simon T, Khalife K, Lim P, Ennezat P-V, Coste P, Le Breton H, Bataille V, Ferrières J, Danchin N. 2014. Prevalence, clinical profile and 3-year survival of acute myocardial infarction patients with and without obstructive coronary lesions: the FAST-MI 2005 registry. International Journal of Cardiology 172:e247–249.
1.
Arsenault BJ, Boekholdt SM, Mora S, DeMicco DA, Bao W, Tardif J-C, Amarenco P, Pedersen T, Barter P, Waters DD. 2014. Impact of high-dose atorvastatin therapy and clinical risk factors on incident aortic valve stenosis in patients with cardiovascular disease (from TNT, IDEAL, and SPARCL). The American Journal of Cardiology 113:1378–1382.
1.
Bainey KR, Gafni A, Rao-Melacini P, Tong W, Steg PG, Faxon DP, Lamy A, Granger CB, Yusuf S, Mehta SR, Investigators T. 2014. The cost implications of an early versus delayed invasive strategy in Acute Coronary Syndromes: the TIMACS study. Journal of Medical Economics 17:415–422.
1.
Balode I, Mintāle I, Latkovskis G, Jēgere S, Narbute I, Bajāre I, Greenlaw N, Steg PG, Ferrari R, Ērglis A, Investigators CR. 2014. Insufficient control of heart rate in stable coronary artery disease patients in Latvia. Medicina (Kaunas, Lithuania) 50:295–302.
1.
Beaugerie L, Carrat F, Colombel J-F, Bouvier A-M, Sokol H, Babouri A, Carbonnel F, Laharie D, Faucheron J-L, Simon T, de Gramont A, Peyrin-Biroulet L, Group CS. 2014. Risk of new or recurrent cancer under immunosuppressive therapy in patients with IBD and previous cancer. Gut 63:1416–1423.
1.
Boekholdt SM, Hovingh GK, Mora S, Arsenault BJ, Amarenco P, Pedersen TR, LaRosa JC, Waters DD, DeMicco DA, Simes RJ, Keech AC, Colquhoun D, Hitman GA, Betteridge DJ, Clearfield MB, Downs JR, Colhoun HM, Gotto AM, Ridker PM, Grundy SM, Kastelein JJP. 2014. Very low levels of atherogenic lipoproteins and the risk for cardiovascular events: a meta-analysis of statin trials. Journal of the American College of Cardiology 64:485–494.
1.
Bonaca MP, Bhatt DL, Braunwald E, Cohen M, Steg PG, Storey RF, Held P, Jensen EC, Sabatine MS. 2014. Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial. American Heart Journal 167:437–444.e5.
1.
Bougouin W, Marijon E, Puymirat E, Defaye P, Celermajer DS, Le Heuzey J-Y, Boveda S, Kacet S, Mabo P, Barnay C, Da Costa A, Deharo J-C, Daubert J-C, Ferrières J, Simon T, Danchin N, Investigators F-MR. 2014. Incidence of sudden cardiac death after ventricular fibrillation complicating acute myocardial infarction: a 5-year cause-of-death analysis of the FAST-MI 2005 registry. European Heart Journal 35:116–122.
1.
Camm AJ, Amarenco P, Haas S, Hess S, Kirchhof P, van Eickels M, Turpie AGG. 2014. XANTUS: rationale and design of a noninterventional study of rivaroxaban for the prevention of stroke in patients with atrial fibrillation. Vascular Health and Risk Management 10:425–434.
1.
Danchin N, Ferrieres J, Guenoun M, Cattan S, Rushton-Smith SK, Greenlaw N, Ferrari R, Steg PG, Investigators C. 2014. Management of outpatients in France with stable coronary artery disease. Findings from the prospeCtive observational LongitudinAl RegIstry oF patients with stable coronary arterY disease (CLARIFY) registry. Archives of Cardiovascular Diseases 107:452–461.
1.
Danchin N, Puymirat E, Simon T. 2014. Door-to-balloon time and mortality. The New England Journal of Medicine 370:179–180.
1.
Danchin N, Puymirat E, Steg PG, Goldstein P, Schiele F, Belle L, Cottin Y, Fajadet J, Khalife K, Coste P, Ferrières J, Simon T, Investigators F-M. 2014. Five-year survival in patients with ST-segment-elevation myocardial infarction according to modalities of reperfusion therapy: the French Registry on Acute ST-Elevation and Non-ST-Elevation Myocardial Infarction (FAST-MI) 2005 Cohort. Circulation 129:1629–1636.
1.
Dossier C, Sellier-Leclerc A-L, Rousseau A, Michel Y, Gautheret-Dejean A, Englender M, Madhi F, Charbit M, Ulinski T, Simon T, Jacqz-Aigrain E, Deschênes G. 2014. Prevalence of herpesviruses at onset of idiopathic nephrotic syndrome. Pediatric Nephrology (Berlin, Germany) 29:2325–2331.
1.
Feldman L, Tubach F, Juliard J-M, Himbert D, Ducrocq G, Sorbets E, Triantafyllou K, Kerner A, Abergel H, Huisse M-G, Roussel R, Esposito-Farèse M, Steg PG, Ajzenberg N. 2014. Impact of diabetes mellitus and metabolic syndrome on acute and chronic on-clopidogrel platelet reactivity in patients with stable coronary artery disease undergoing drug-eluting stent placement. American Heart Journal 168:940–947.e5.
1.
Fox KAA, Fitzgerald G, Puymirat E, Huang W, Carruthers K, Simon T, Coste P, Monsegu J, Gabriel Steg P, Danchin N, Anderson F. 2014. Should patients with acute coronary disease be stratified for management according to their risk? Derivation, external validation and outcomes using the updated GRACE risk score. BMJ open 4:e004425.
1.
Fox K, Ford I, Steg PG, Tardif J-C, Tendera M, Ferrari R, Investigators S. 2014. Ivabradine in stable coronary artery disease without clinical heart failure. The New England Journal of Medicine 371:1091–1099.
1.
Fruchart J-C, Davignon J, Hermans MP, Al-Rubeaan K, Amarenco P, Assmann G, Barter P, Betteridge J, Bruckert E, Cuevas A, Farnier M, Ferrannini E, Fioretto P, Genest J, Ginsberg HN, Gotto AM, Hu D, Kadowaki T, Kodama T, Krempf M, Matsuzawa Y, Núñez-Cortés JM, Monfil CC, Ogawa H, Plutzky J, Rader DJ, Sadikot S, Santos RD, Shlyakhto E, Sritara P, Sy R, Tall A, Tan CE, Tokgözoğlu L, Toth PP, Valensi P, Wanner C, Zambon A, Zhu J, Zimmet P, Residual Risk Reduction I. 2014. Residual macrovascular risk in 2013: what have we learned? Cardiovascular Diabetology 13:26.
1.
Gamra H, Murin J, Chiang C-E, Naditch-Brûlé L, Brette S, Steg PG, Realise AF investigators. 2014. Use of antithrombotics in atrial fibrillation in Africa, Europe, Asia and South America: insights from the International RealiseAF Survey. Archives of Cardiovascular Diseases 107:77–87.
1.
Gomez I, Benyahia C, Louedec L, Leséche G, Jacob M-P, Longrois D, Norel X. 2014. Decreased PGE₂ content reduces MMP-1 activity and consequently increases collagen density in human varicose vein. PloS One 9:e88021.
1.
Halcox JPJ, Roy C, Tubach F, Banegas JR, Dallongeville J, De Backer G, Guallar E, Sazova O, Medina J, Perk J, Steg PG, Rodríguez-Artalejo F, Borghi C. 2014. C-reactive protein levels in patients at cardiovascular risk: EURIKA study. BMC cardiovascular disorders 14:25.
1.
Hamon M, Nienaber CA, Galli S, Huber K, Lipiecki J, Hill JM, Amabile N, Bernstein D, Deliargyris E, Lafont A, Steg PG. 2014. Bivalirudin in percutaneous coronary intervention: the EUROpean BiValIrudin UtiliSatION in Practice (EUROVISION) Registry. International Journal of Cardiology 173:290–294.
1.
Holmes MV, Simon T, Exeter HJ, Hingorani AD, Sabatine MS, Mallat Z, Casas JP, Talmud PJ. 2014. Reply: limits of Mendelian randomization analyses in selection of secretory phospholipase A2-IIA as a valid therapeutic target for prevention of cardiovascular disease. Journal of the American College of Cardiology 63:943.
1.
Huber K, Bates ER, Valgimigli M, Wallentin L, Kristensen SD, Anderson JL, Lopez Sendon JL, Tubaro M, Granger CB, Bode C, Ohman EM, Steg PG. 2014. Antiplatelet and anticoagulation agents in acute coronary syndromes: what is the current status and what does the future hold? American Heart Journal 168:611–621.
1.
Hyafil F, Klein I, Desilles J-P, Mazighi M, Le Guludec D, Amarenco P. 2014. Rupture of nonstenotic carotid plaque as a cause of ischemic stroke evidenced by multimodality imaging. Circulation 129:130–131.
1.
Hylek EM, Held C, Alexander JH, Lopes RD, De Caterina R, Wojdyla DM, Huber K, Jansky P, Steg PG, Hanna M, Thomas L, Wallentin L, Granger CB. 2014. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes. Journal of the American College of Cardiology 63:2141–2147.
1.
Inoue M, Olivot J-M, Labreuche J, Mlynash M, Tai W, Albucher J-F, Meseguer E, Amarenco P, Mazighi M. 2014. Impact of diffusion-weighted imaging Alberta stroke program early computed tomography score on the success of endovascular reperfusion therapy. Stroke 45:1992–1998.
1.
Jolly SS, Cairns J, Yusuf S, Meeks B, Shestakovska O, Thabane L, Niemelä K, Steg PG, Bertrand OF, Rao SV, Avezum A, Cantor WJ, Pancholy SB, Moreno R, Gershlick A, Bhindi R, Welsh RC, Cheema AN, Lavi S, Rokoss M, Džavík V. 2014. Design and rationale of the TOTAL trial: a randomized trial of routine aspiration ThrOmbecTomy with percutaneous coronary intervention (PCI) versus PCI ALone in patients with ST-elevation myocardial infarction undergoing primary PCI. American Heart Journal 167:315–321.e1.
1.
Jolly SS, Cairns J, Yusuf S, Niemela K, Steg PG, Worthley M, Ferrari E, Cantor WJ, Fung A, Valettas N, Rokoss M, Olivecrona GK, Widimsky P, Cheema AN, Gao P, Mehta SR, Investigators R. 2014. Procedural volume and outcomes with radial or femoral access for coronary angiography and intervention. Journal of the American College of Cardiology 63:954–963.
1.
Khatri P, Yeatts SD, Mazighi M, Broderick JP, Liebeskind DS, Demchuk AM, Amarenco P, Carrozzella J, Spilker J, Foster LD, Goyal M, Hill MD, Palesch YY, Jauch EC, Haley EC, Vagal A, Tomsick TA, Trialists II. 2014. Time to angiographic reperfusion and clinical outcome after acute ischaemic stroke: an analysis of data from the Interventional Management of Stroke (IMS III) phase 3 trial. The Lancet Neurology 13:567–574.
1.
Kohli P, Steg PG, Cannon CP, Smith SC, Eagle KA, Ohman EM, Alberts MJ, Hoffman E, Guo J, Simon T, Sorbets E, Goto S, Bhatt DL, Investigators RR. 2014. NSAID use and association with cardiovascular outcomes in outpatients with stable atherothrombotic disease. The American Journal of Medicine 127:53–60.e1.
1.
Lavallée P, Amarenco P. 2014. TIA clinic: a major advance in management of transient ischemic attacks. Frontiers of Neurology and Neuroscience 33:30–40.
1.
Lavallée P, Amarenco P. 2014. Stroke subtypes and interventional studies for transient ischemic attack. Frontiers of Neurology and Neuroscience 33:135–146.
1.
Lavallée PC, Labreuche J, Fox KM, Lavados P, Mattle H, Steg PG, Amarenco P, Perform O, Investigators A. 2014. Influenza vaccination and cardiovascular risk in patients with recent TIA and stroke. Neurology 82:1905–1913.
1.
Lindholm D, Varenhorst C, Cannon CP, Harrington RA, Himmelmann A, Maya J, Husted S, Steg PG, Cornel JH, Storey RF, Stevens SR, Wallentin L, James SK. 2014. Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial. European Heart Journal 35:2083–2093.
1.
Mahaffey KW, Held C, Wojdyla DM, James SK, Katus HA, Husted S, Steg PG, Cannon CP, Becker RC, Storey RF, Khurmi NS, Nicolau JC, Yu C-M, Ardissino D, Budaj A, Morais J, Montgomery D, Himmelmann A, Harrington RA, Wallentin L, Investigators P. 2014. Ticagrelor effects on myocardial infarction and the impact of event adjudication in the PLATO (Platelet Inhibition and Patient Outcomes) trial. Journal of the American College of Cardiology 63:1493–1499.
1.
Mas J-L, Arquizan C, Calvet D, Viguier A, Albucher J-F, Piquet P, Garnier P, Viader F, Giroud M, Hosseini H, Hinzelin G, Favrole P, Hénon H, Neau J-P, Ducrocq X, Padovani R, Milandre L, Rouanet F, Wolff V, Saudeau D, Mahagne M-H, Sablot D, Amarenco P, Larrue V, Beyssen B, Leys D, Moulin T, Lièvre M, Chatellier G, Investigators E-S. 2014. Long-term follow-up study of endarterectomy versus angioplasty in patients with symptomatic severe carotid stenosis trial. Stroke 45:2750–2756.
1.
Meseguer E, Labreuche J, Gonzalez-Valcarcel J, Sirimarco G, Guidoux C, Cabrejo L, Lavallee PC, Klein IF, Amarenco P, Mazighi M. 2014. The smoking paradox: impact of smoking on recanalization in the setting of intra-arterial thrombolysis. Cerebrovascular Diseases Extra 4:84–91.
1.
Ovbiagele B, Goldstein LB, Amarenco P, Messig M, Sillesen H, Callahan A, Hennerici MG, Zivin J, Welch KMA, Investigators S. 2014. Prediction of major vascular events after stroke: the stroke prevention by aggressive reduction in cholesterol levels trial. Journal of Stroke and Cerebrovascular Diseases: The Official Journal of National Stroke Association 23:778–784.
1.
Picard FA, Gueret P, Laissy J-P, Champagne S, Leclercq F, Carrié D, Juliard J-M, Henry P, Niarra R, Chatellier G, Steg PG. 2014. Epicardial adipose tissue thickness correlates with the presence and severity of angiographic coronary artery disease in stable patients with chest pain. PloS One 9:e110005.
1.
Puymirat E, Aissaoui N, Cottin Y, Vanzetto G, Carrié D, Isaaz K, Valy Y, Tchetche D, Schiele F, Steg PG, Simon T, Danchin N. 2014. Effect of coronary thrombus aspiration during primary percutaneous coronary intervention on one-year survival (from the FAST-MI 2010 registry). The American Journal of Cardiology 114:1651–1657.
1.
Puymirat E, Schiele F, Steg PG, Blanchard D, Isorni M-A, Silvain J, Goldstein P, Guéret P, Mulak G, Berard L, Bataille V, Cattan S, Ferrières J, Simon T, Danchin N, investigators F-M. 2014. Determinants of improved one-year survival in non-ST-segment elevation myocardial infarction patients: insights from the French FAST-MI program over 15 years. International Journal of Cardiology 177:281–286.
1.
Rodés-Cabau J, Kahlert P, Neumann F-J, Schymik G, Webb JG, Amarenco P, Brott T, Garami Z, Gerosa G, Lefèvre T, Plicht B, Pocock SJ, Schlamann M, Thomas M, Diamond B, Merioua I, Beyersdorf F, Vahanian A. 2014. Feasibility and exploratory efficacy evaluation of the Embrella Embolic Deflector system for the prevention of cerebral emboli in patients undergoing transcatheter aortic valve replacement: the PROTAVI-C pilot study. JACC Cardiovascular interventions 7:1146–1155.
1.
Rothan-Tondeur M, Courcier S, Béhier J-M, participants of round table N of GXLJPNLM-C, Leblanc J, Peoch N, Lefort M-C, Barthélémy P, Bassompierre F, Bilbault P, Déal C, Diebolt V, Fraleux M, François B, Gambotti L, Lévy-Marchal C, Misse C, Roussel C, Sibenaler C, Simon T, Tavernier B, Thoby F. 2014. Promoting the place of the allied health professions in clinical research. Therapie 69:271–290.
1.
Rouchaud A, Klein I, Amarenco P, Mazighi M, Pacchioni A, Torsello G, Reimers B, van Sambeek MRHM, Tielbeek AV, Teijink JAW, Cuypers PW. 2014. How should I treat a symptomatic post dissection carotid aneurysm? EuroIntervention: Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 9:1121–1123.
1.
Schwartz GG, Bessac L, Berdan LG, Bhatt DL, Bittner V, Diaz R, Goodman SG, Hanotin C, Harrington RA, Jukema JW, Mahaffey KW, Moryusef A, Pordy R, Roe MT, Rorick T, Sasiela WJ, Shirodaria C, Szarek M, Tamby J-F, Tricoci P, White H, Zeiher A, Steg PG. 2014. Effect of alirocumab, a monoclonal antibody to PCSK9, on long-term cardiovascular outcomes following acute coronary syndromes: rationale and design of the ODYSSEY outcomes trial. American Heart Journal 168:682–689.
1.
Seronde MF, Geha R, Puymirat E, Chaib A, Simon T, Berard L, Drouet E, Bataille V, Danchin N, Schiele F. 2014. Discharge heart rate and mortality after acute myocardial infarction. The American Journal of Medicine 127:954–962.
1.
Sirimarco G, Labreuche J, Bruckert E, Goldstein LB, Fox KM, Rothwell PM, Amarenco P, Perform, Investigators S, Committees. 2014. Atherogenic dyslipidemia and residual cardiovascular risk in statin-treated patients. Stroke 45:1429–1436.
1.
Sorbets E, Labreuche J, Simon T, Delorme L, Danchin N, Amarenco P, Goto S, Meune C, Eagle KA, Bhatt DL, Steg PG. 2014. Renin-angiotensin system antagonists and clinical outcomes in stable coronary artery disease without heart failure. European Heart Journal 35:1760–1768.
1.
Steg PG, Cheong AP. 2014. Death (after percutaneous coronary intervention) is no longer what it used to be. Circulation 129:1267–1269.
1.
Steg PG, De Silva R. 2014. Beta-blockers in asymptomatic coronary artery disease: no benefit or no evidence? Journal of the American College of Cardiology 64:253–255.
1.
Steg PG, Greenlaw N, Tendera M, Tardif J-C, Ferrari R, Al-Zaibag M, Dorian P, Hu D, Shalnova S, Sokn FJ, Ford I, Fox KM, Prospective Observational Longitudinal Registry of Patients With Stable Coronary Artery Disease I. 2014. Prevalence of anginal symptoms and myocardial ischemia and their effect on clinical outcomes in outpatients with stable coronary artery disease: data from the International Observational CLARIFY Registry. JAMA internal medicine 174:1651–1659.
1.
Tilly P, Charles A-L, Ludwig S, Slimani F, Gross S, Meilhac O, Geny B, Stefansson K, Gurney ME, Fabre J-E. 2014. Blocking the EP3 receptor for PGE2 with DG-041 decreases thrombosis without impairing haemostatic competence. Cardiovascular Research 101:482–491.
1.
Touboul P-J, Labreuche J, Bruckert E, Schargrodsky H, Prati P, Tosetto A, Hernandez-Hernandez R, Woo K-S, Silva H, Vicaut E, Amarenco P. 2014. HDL-C, triglycerides and carotid IMT: a meta-analysis of 21,000 patients with automated edge detection IMT measurement. Atherosclerosis 232:65–71.
1.
Tran-Dinh A, Levoye A, Lambert G, Louedec L, Journé C, Meilhac O, Amarenco P. 2014. Low levels of low-density lipoprotein-C associated with proprotein convertase subtilisin kexin 9 inhibition do not increase the risk of hemorrhagic transformation. Stroke 45:3086–3088.
1.
Wallentin L, Becker RC, Cannon CP, Held C, Himmelmann A, Husted S, James SK, Katus HS, Mahaffey KW, Pieper KS, Storey RF, Steg PG, Harrington RA. 2014. Review of the accumulated PLATO documentation supports reliable and consistent superiority of ticagrelor over clopidogrel in patients with acute coronary syndrome: Commentary on: DiNicolantonio JJ, Tomek A, Inactivations, deletions, non-adjudications, and downgrades of clinical endpoints on ticagrelor: serious concerns over the reliability of the PLATO trial, International Journal of Cardiology, 2013. International Journal of Cardiology 170:e59–62.
1.
Wallentin L, Becker RC, Cannon CP, Held C, Himmelmann A, Husted S, James SK, Katus HA, Mahaffey KM, Pieper KS, Storey RF, Steg PG, Harrington RA, Investigators P. 2014. No misrepresentation of vital status follow-up in PLATO: predefined analyses guarantee the integrity of the benefits of ticagrelor over clopidogrel in the PLATO trial: Commentary on: DiNicolantonio JJ, Tomek A, Misrepresentation of vital status follow-up: challenging the integrity of the PLATO trial and the claimed mortality benefit of ticagrelor versus clopidogrel, International Journal of Cardiology, 2013 Serebruany VL. Discrepancies in the primary PLATO trial publication and the FDA reviews, International Journal of Cardiology, 2014. International Journal of Cardiology 176:300–302.
1.
Wallentin L, Kristensen SD, Anderson JL, Tubaro M, Sendon JLL, Granger CB, Bode C, Huber K, Bates ER, Valgimigli M, Steg PG, Ohman EM. 2014. How can we optimize the processes of care for acute coronary syndromes to improve outcomes? American Heart Journal 168:622–631.
1.
Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S, Hylek EM, Al-Khatib SM, Alexander JH, Alings M, Amerena J, Ansell J, Aylward P, Bartunek J, Commerford P, De Caterina R, Erol C, Harjola V-P, Held C, Horowitz J, Huber K, Husted S, Keltai M, Lanas F, Lisheng L, McMurray JJV, Oh B-H, Rosenqvist M, Ruzyllo W, Steg PG, Vinereanu D, Xavier D, Granger CB. 2014. Response to letter regarding article, “Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation.” Circulation 129:e21–22.
1.
Wang K-L, Wu C-H, Huang C-C, Wu T-C, Naditch-Brûlé L, Steg PG, Lin S-J, Chiang C-E. 2014. Complexity of atrial fibrillation patients and management in Chinese ethnicity in routine daily practice: insights from the RealiseAF Taiwanese cohort. Journal of Cardiology 64:211–217.
1.
Welsh RC, Van de Werf F, Westerhout CM, Goldstein P, Gershlick AH, Wilcox RG, Danays T, Bluhmki E, Lopes RD, Steg PG, Armstrong PW. 2014. Outcomes of a pharmacoinvasive strategy for successful versus failed fibrinolysis and primary percutaneous intervention in acute myocardial infarction (from the STrategic Reperfusion Early After Myocardial Infarction [STREAM] study). The American Journal of Cardiology 114:811–819.
1.
Wiernik E, Nabi H, Pannier B, Czernichow S, Hanon O, Simon T, Simon J-M, Thomas F, Ducolombier C, Danchin N, Limosin F, Consoli SM, Lemogne C. 2014. Perceived stress, sex and occupational status interact to increase the risk of future high blood pressure: the IPC cohort study. Journal of Hypertension 32:1979–1986; discussion 1986.
1.
Zaidat OO, Castonguay AC, Nguyen TN, Becker KJ, Derdeyn CP, Nelson PK, Amarenco P, Brott TG. 2014. Impact of SAMMPRIS on the future of intracranial atherosclerotic disease management: polling results from the ICAD symposium at the International Stroke Conference. Journal of Neurointerventional Surgery 6:225–230.
1.
Zeymer U, van ’t Hof A, Adgey J, Nibbe L, Clemmensen P, Cavallini C, ten Berg J, Coste P, Huber K, Deliargyris EN, Day J, Bernstein D, Goldstein P, Hamm C, Steg PG. 2014. Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial. European Heart Journal 35:2460–2467.

2013

1.
Abboud H, Labreuche J, Arauz A, Bryer A, Lavados PG, Massaro A, Munoz Collazos M, Steg PG, Yamout BI, Vicaut E, Amarenco P, Investigators OR. 2013. Demographics, socio-economic characteristics, and risk factor prevalence in patients with non-cardioembolic ischaemic stroke in low- and middle-income countries: the OPTIC registry. International Journal of Stroke: Official Journal of the International Stroke Society 8 Suppl A100:4–13.
1.
Amarenco P, Lavallée PC, Labreuche J, Ducrocq G, Juliard J-M, Feldman L, Cabrejo L, Meseguer E, Guidoux C, Adraï V, Ratani S, Kusmierek J, Lapergue B, Klein IF, Gongora-Rivera F, Jaramillo A, Abboud H, Olivot J-M, Mazighi M, Touboul P-J, Steg PG. 2013. Coronary artery disease and risk of major vascular events after cerebral infarction. Stroke 44:1505–1511.
1.
Banegas JR, López-García E, Dallongeville J, Guallar E, Halcox JP, Borghi C, Massó-González EL, Sazova O, Perk J, Steg PG, De Backer G, Rodríguez-Artalejo F. 2013. Achievement of lipoprotein goals among patients with metabolic syndrome at high cardiovascular risk across Europe. The EURIKA study. International Journal of Cardiology 166:210–214.
1.
Bao Dang Q, Lapergue B, Tran-Dinh A, Diallo D, Moreno J-A, Mazighi M, Romero IA, Weksler B, Michel J-B, Amarenco P, Meilhac O. 2013. High-density lipoproteins limit neutrophil-induced damage to the blood-brain barrier in vitro. Journal of Cerebral Blood Flow and Metabolism: Official Journal of the International Society of Cerebral Blood Flow and Metabolism 33:575–582.
1.
Beaugerie L, Svrcek M, Seksik P, Bouvier A-M, Simon T, Allez M, Brixi H, Gornet J-M, Altwegg R, Beau P, Duclos B, Bourreille A, Faivre J, Peyrin-Biroulet L, Fléjou J-F, Carrat F, Group CS. 2013. Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease. Gastroenterology 145:166–175.e8.
1.
Benyahia C, Boukais K, Gomez I, Silverstein A, Clapp L, Fabre A, Danel C, Leséche G, Longrois D, Norel X. 2013. A comparative study of PGI2 mimetics used clinically on the vasorelaxation of human pulmonary arteries and veins, role of the DP-receptor. Prostaglandins & Other Lipid Mediators 107:48–55.
1.
Boekholdt SM, Arsenault BJ, Hovingh GK, Mora S, Pedersen TR, Larosa JC, Welch KMA, Amarenco P, Demicco DA, Tonkin AM, Sullivan DR, Kirby A, Colhoun HM, Hitman GA, Betteridge DJ, Durrington PN, Clearfield MB, Downs JR, Gotto AM, Ridker PM, Kastelein JJP. 2013. Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis. Circulation 128:1504–1512.
1.
Bossone E, Corteville DC, Harris KM, Suzuki T, Fattori R, Hutchison S, Ehrlich MP, Pyeritz RE, Steg PG, Greason K, Evangelista A, Kline-Rogers E, Montgomery DG, Isselbacher EM, Nienaber CA, Eagle KA. 2013. Stroke and outcomes in patients with acute type A aortic dissection. Circulation 128:S175–179.
1.
Clària J, Norel X, Bannenberg G. 2013. Publication of the special issue “Fourth European workshop on lipid mediators.” Prostaglandins & Other Lipid Mediators 107:1–3.
1.
Dagouassat M, Gagliolo J-M, Chrusciel S, Bourin M-C, Duprez C, Caramelle P, Boyer L, Hue S, Stern J-B, Validire P, Longrois D, Norel X, Dubois-Randé J-L, Le Gouvello S, Adnot S, Boczkowski J. 2013. The cyclooxygenase-2-prostaglandin E2 pathway maintains senescence of chronic obstructive pulmonary disease fibroblasts. American Journal of Respiratory and Critical Care Medicine 187:703–714.
1.
Danchin N, Puymirat E, Simon T. 2013. The (possibly) deceptive figures of decreased coronary heart disease mortality in Europe. European Heart Journal 34:3014–3016.
1.
Deplanque D, Lavallee PC, Labreuche J, Gongora-Rivera F, Jaramillo A, Brenner D, Abboud H, Klein IF, Touboul P-J, Vicaut E, Amarenco P, Lacunar BI. 2013. Cerebral and extracerebral vasoreactivity in symptomatic lacunar stroke patients: a case-control study. International Journal of Stroke: Official Journal of the International Stroke Society 8:413–421.
1.
Desilles J-P, Meseguer E, Labreuche J, Lapergue B, Sirimarco G, Gonzalez-Valcarcel J, Lavallée P, Cabrejo L, Guidoux C, Klein I, Amarenco P, Mazighi M. 2013. Diabetes mellitus, admission glucose, and outcomes after stroke thrombolysis: a registry and systematic review. Stroke 44:1915–1923.
1.
Desilles J-P, Rouchaud A, Labreuche J, Meseguer E, Laissy J-P, Serfaty J-M, Lapergue B, Klein IF, Guidoux C, Cabrejo L, Sirimarco G, Lavallée PC, Schouman-Claeys E, Amarenco P, Mazighi M. 2013. Blood-brain barrier disruption is associated with increased mortality after endovascular therapy. Neurology 80:844–851.
1.
Ducrocq G, Amarenco P, Labreuche J, Alberts MJ, Mas J-L, Ohman EM, Goto S, Lavallée P, Bhatt DL, Steg PG. 2013. A history of stroke/transient ischemic attack indicates high risks of cardiovascular event and hemorrhagic stroke in patients with coronary artery disease. Circulation 127:730–738.
1.
Fardet L, Antuna-Puente B, Vatier C, Cervera P, Touati A, Simon T, Capeau J, Fève B, Bastard J-P. 2013. Adipokine profile in glucocorticoid-treated patients: baseline plasma leptin level predicts occurrence of lipodystrophy. Clinical Endocrinology 78:43–51.
1.
Fassa A-A, Wijns W, Kolh P, Steg PG. 2013. Benefit of revascularization for stable ischaemic heart disease: the jury is still out. European Heart Journal 34:1534–1538.
1.
Fox K, Bousser M-G, Amarenco P, Chamorro A, Fisher M, Ford I, Hennerici MG, Mattle HP, Rothwell PM, Investigators PS. 2013. Heart rate is a prognostic risk factor for myocardial infarction: a post hoc analysis in the PERFORM (Prevention of cerebrovascular and cardiovascular Events of ischemic origin with teRutroban in patients with a history oF ischemic strOke or tRansient ischeMic attack) study population. International Journal of Cardiology 168:3500–3505.
1.
Fox K, Ford I, Steg PG, Tardif J-C, Tendera M, Ferrari R. 2013. Rationale, design, and baseline characteristics of the Study assessInG the morbidity-mortality beNefits of the If inhibitor ivabradine in patients with coronarY artery disease (SIGNIFY trial): a randomized, double-blind, placebo-controlled trial of ivabradine in patients with stable coronary artery disease without clinical heart failure. American Heart Journal 166:654–661.e6.
1.
Fox K, Komajda M, Ford I, Robertson M, Böhm M, Borer JS, Steg PG, Tavazzi L, Tendera M, Ferrari R, Swedberg K. 2013. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. European Heart Journal 34:2263–2270.
1.
Gomez I, Benyahia C, Le Dall J, Payré C, Louedec L, Leséche G, Lambeau G, Longrois D, Norel X. 2013. Absence of inflammatory conditions in human varicose saphenous veins. Inflammation Research: Official Journal of the European Histamine Research Society . [et Al] 62:299–308.
1.
Gomez I, Foudi N, Longrois D, Norel X. 2013. The role of prostaglandin E2 in human vascular inflammation. Prostaglandins, Leukotrienes, and Essential Fatty Acids 89:55–63.
1.
Guidoux C, Mazighi M, Lavallée P, Labreuche J, Meseguer E, Cabrejo L, Messika-Zeitoun D, Escoubet B, Touboul P-J, Steg PG, Amarenco P. 2013. Aortic arch atheroma in transient ischemic attack patients. Atherosclerosis 231:124–128.
1.
Hess CN, Schulte PJ, Newby LK, Steg PG, Dalby AJ, Schweiger MJ, Lewis BS, Armstrong PW, Califf RM, van de Werf F, Harrington RA. 2013. Duration of eptifibatide infusion after percutaneous coronary intervention and outcomes among high-risk patients with non-ST-segment elevation acute coronary syndrome: insights from EARLY ACS. European Heart Journal Acute Cardiovascular Care 2:246–255.
1.
Holmes MV, Simon T, Exeter HJ, Folkersen L, Asselbergs FW, Guardiola M, Cooper JA, Palmen J, Hubacek JA, Carruthers KF, Horne BD, Brunisholz KD, Mega JL, van Iperen EPA, Li M, Leusink M, Trompet S, Verschuren JJW, Hovingh GK, Dehghan A, Nelson CP, Kotti S, Danchin N, Scholz M, Haase CL, Rothenbacher D, Swerdlow DI, Kuchenbaecker KB, Staines-Urias E, Goel A, van ’t Hooft F, Gertow K, de Faire U, Panayiotou AG, Tremoli E, Baldassarre D, Veglia F, Holdt LM, Beutner F, Gansevoort RT, Navis GJ, Mateo Leach I, Breitling LP, Brenner H, Thiery J, Dallmeier D, Franco-Cereceda A, Boer JMA, Stephens JW, Hofker MH, Tedgui A, Hofman A, Uitterlinden AG, Adamkova V, Pitha J, Onland-Moret NC, Cramer MJ, Nathoe HM, Spiering W, Klungel OH, Kumari M, Whincup PH, Morrow DA, Braund PS, Hall AS, Olsson AG, Doevendans PA, Trip MD, Tobin MD, Hamsten A, Watkins H, Koenig W, Nicolaides AN, Teupser D, Day INM, Carlquist JF, Gaunt TR, Ford I, Sattar N, Tsimikas S, Schwartz GG, Lawlor DA, Morris RW, Sandhu MS, Poledne R, Maitland-van der Zee AH, Khaw K-T, Keating BJ, van der Harst P, Price JF, Mehta SR, Yusuf S, Witteman JCM, Franco OH, Jukema JW, de Knijff P, Tybjaerg-Hansen A, Rader DJ, Farrall M, Samani NJ, others. 2013. Secretory phospholipase A(2)-IIA and cardiovascular disease: a mendelian randomization study. Journal of the American College of Cardiology 62:1966–1976.
1.
James SK, Pieper KS, Cannon CP, Storey RF, Becker RC, Steg PG, Wallentin L, Harrington RA, group P study. 2013. Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials. Stroke 44:1477–1479.
1.
James SK, Storey RF, Pieper KS, Cannon CP, Becker RC, Steg PG, Wallentin L, Harrington RA, Group PS. 2013. Response to letter regarding article, “Ticagrelor in patients with acute coronary syndromes and stroke: interpretation of subgroups in clinical trials.” Stroke 44:e95–96.
1.
Jolly SS, Cairns J, Niemela K, Steg PG, Natarajan MK, Cheema AN, Rao SV, Cantor WJ, Džavík V, Budaj A, Sheth T, Valentin V, Fung A, Widimsky P, Ferrari E, Gao P, Jedrzejowski B, Mehta SR, Investigators R. 2013. Effect of radial versus femoral access on radiation dose and the importance of procedural volume: a substudy of the multicenter randomized RIVAL trial. JACC Cardiovascular interventions 6:258–266.
1.
Juliard J-M, Golmard JL, Himbert D, Feldman LJ, Delorme L, Ducrocq G, Descoutures F, Sorbets E, Garbarz E, Boudvillain O, Aubry P, Vahanian A, Steg PG. 2013. Comparison of hospital mortality during ST-segment elevation myocardial infarction in the era of reperfusion therapy in women versus men and in older versus younger patients. The American Journal of Cardiology 111:1708–1713.
1.
Lapergue B, Dang BQ, Desilles J-P, Ortiz-Munoz G, Delbosc S, Loyau S, Louedec L, Couraud P-O, Mazighi M, Michel J-B, Meilhac O, Amarenco P. 2013. High-density lipoprotein-based therapy reduces the hemorrhagic complications associated with tissue plasminogen activator treatment in experimental stroke. Stroke 44:699–707.
1.
Lavallée PC, Cabrejo L, Labreuche J, Mazighi M, Meseguer E, Guidoux C, Abboud H, Lapergue B, Klein IF, Olivot J-M, Sirimarco G, Gonzales-Valcarcel J, Touboul P-J, Amarenco P. 2013. Spectrum of transient visual symptoms in a transient ischemic attack cohort. Stroke 44:3312–3317.
1.
Le Jeunne C, Billon N, Dandon A, participants of round table N° 3 of Giens X, Berdaï D, Adgibi Y, Bergmann J-F, Bordet R, Carpentier A, Cohn E, Courcier S, Girault D, Goni S, Jolliet P, Liard F, Prot-Labarthe S, Simon T, Vernotte C, Westerloppe J. 2013. Off-label prescriptions: how to identify them, frame them, announce them and monitor them in practice? Therapie 68:225–239.
1.
Lefevre JH, Rousseau A, Svrcek M, Parc Y, Simon T, Tiret E, French Research Group of Rectal Cancer S. 2013. A multicentric randomized controlled trial on the impact of lengthening the interval between neoadjuvant radiochemotherapy and surgery on complete pathological response in rectal cancer (GRECCAR-6 trial): rationale and design. BMC cancer 13:417.
1.
Lim P, Moutereau S, Simon T, Gallet R, Probst V, Ferrieres J, Gueret P, Danchin N. 2013. Usefulness of fetuin-A and C-reactive protein concentrations for prediction of outcome in acute coronary syndromes (from the French Registry of Acute ST-Elevation Non-ST-Elevation Myocardial Infarction [FAST-MI]). The American Journal of Cardiology 111:31–37.
1.
Mazighi M, Chaudhry SA, Ribo M, Khatri P, Skoloudik D, Mokin M, Labreuche J, Meseguer E, Yeatts SD, Siddiqui AH, Broderick J, Molina CA, Qureshi AI, Amarenco P. 2013. Impact of onset-to-reperfusion time on stroke mortality: a collaborative pooled analysis. Circulation 127:1980–1985.
1.
Mehran R, Baber U, Steg PG, Ariti C, Weisz G, Witzenbichler B, Henry TD, Kini AS, Stuckey T, Cohen DJ, Berger PB, Iakovou I, Dangas G, Waksman R, Antoniucci D, Sartori S, Krucoff MW, Hermiller JB, Shawl F, Gibson CM, Chieffo A, Alu M, Moliterno DJ, Colombo A, Pocock S. 2013. Cessation of dual antiplatelet treatment and cardiac events after percutaneous coronary intervention (PARIS): 2 year results from a prospective observational study. Lancet (London, England) 382:1714–1722.
1.
Meyer M, Sellam J, Fellahi S, Kotti S, Bastard J-P, Meyer O, Lioté F, Simon T, Capeau J, Berenbaum F. 2013. Serum level of adiponectin is a surrogate independent biomarker of radiographic disease progression in early rheumatoid arthritis: results from the ESPOIR cohort. Arthritis Research & Therapy 15:R210.
1.
Mosimann PJ, Sirimarco G, Meseguer E, Serfaty J-M, Laissy J-P, Labreuche J, Lapergue B, Gonzalez-Valcarcel J, Lavallée PC, Cabrejo L, Guidoux C, Klein IF, Olivot J-M, Schouman-Claeys E, Amarenco P, Mazighi M. 2013. Is intracerebral hemorrhage a time-dependent phenomenon after successful combined intravenous and intra-arterial therapy? Stroke 44:806–808.
1.
Olivot J-M, Mosimann PJ, Labreuche J, Inoue M, Meseguer E, Desilles J-P, Rouchaud A, Klein IF, Straka M, Bammer R, Mlynash M, Amarenco P, Albers GW, Mazighi M. 2013. Impact of diffusion-weighted imaging lesion volume on the success of endovascular reperfusion therapy. Stroke 44:2205–2211.
1.
Ozen G, Topal G, Gomez I, Ghorreshi A, Boukais K, Benyahia C, Kanyinda L, Longrois D, Teskin O, Uydes-Dogan BS, Norel X. 2013. Control of human vascular tone by prostanoids derived from perivascular adipose tissue. Prostaglandins & Other Lipid Mediators 107:13–17.
1.
Puymirat E, Aïssaoui N, Collet J-P, Chaib A, Bonnet J-L, Bataille V, Drouet E, Mulak G, Ferrières J, Blanchard D, Simon T, Danchin N. 2013. Comparison of bleeding complications and one-year survival of low molecular weight heparin versus unfractioned heparin for acute myocardial infarction in elderly patients. The FAST-MI registry. International Journal of Cardiology 166:106–110.
1.
Saadi-Thiers K, Huck O, Simonis P, Tilly P, Fabre J-E, Tenenbaum H, Davideau J-L. 2013. Periodontal and systemic responses in various mice models of experimental periodontitis: respective roles of inflammation duration and Porphyromonas gingivalis infection. Journal of Periodontology 84:396–406.
1.
Sellam J, Kotti S, Fellahi S, Bastard J-P, Meyer M, Lioté F, Meyer O, Simon T, Capeau J, Berenbaum F. 2013. Serum hepcidin level is not an independent surrogate biomarker of disease activity or of radiographic progression in rheumatoid arthritis: results from the ESPOIR cohort. Annals of the Rheumatic Diseases 72:312–314.
1.
Simon T, Taleb S, Danchin N, Laurans L, Rousseau B, Cattan S, Montely J-M, Dubourg O, Tedgui A, Kotti S, Mallat Z. 2013. Circulating levels of interleukin-17 and cardiovascular outcomes in patients with acute myocardial infarction. European Heart Journal 34:570–577.
1.
Sirimarco G, Amarenco P, Labreuche J, Touboul P-J, Alberts M, Goto S, Rother J, Mas J-L, Bhatt DL, Steg PG, Investigators RR. 2013. Carotid atherosclerosis and risk of subsequent coronary event in outpatients with atherothrombosis. Stroke 44:373–379.
1.
Sirimarco G, Lavallée PC, Labreuche J, Meseguer E, Cabrejo L, Guidoux C, Klein IF, Olivot J-M, Abboud H, Adraï V, Kusmierek J, Ratani S, Touboul P-J, Mazighi M, Steg PG, Amarenco P. 2013. Overlap of diseases underlying ischemic stroke: the ASCOD phenotyping. Stroke 44:2427–2433.
1.
Stefanini GG, Baber U, Windecker S, Morice M-C, Sartori S, Leon MB, Stone GW, Serruys PW, Wijns W, Weisz G, Camenzind E, Steg PG, Smits PC, Kandzari D, Von Birgelen C, Galatius S, Jeger RV, Kimura T, Mikhail GW, Itchhaporia D, Mehta L, Ortega R, Kim H-S, Valgimigli M, Kastrati A, Chieffo A, Mehran R. 2013. Safety and efficacy of drug-eluting stents in women: a patient-level pooled analysis of randomised trials. Lancet (London, England) 382:1879–1888.
1.
Steg PG, Bhatt DL, Hamm CW, Stone GW, Gibson CM, Mahaffey KW, Leonardi S, Liu T, Skerjanec S, Day JR, Iwaoka RS, Stuckey TD, Gogia HS, Gruberg L, French WJ, White HD, Harrington RA, Investigators C. 2013. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet (London, England) 382:1981–1992.
1.
Steg PG, Mehta SR, Pollack CV, Bode C, Cohen M, French WJ, Hoekstra J, Rao SV, Ruzyllo W, Ruiz-Nodar JM, Sabaté M, Widimsky P, Kiss RG, Navarro Estrada JL, Hod H, Kerkar P, Guneri S, Sezer M, Ruda M, Nicolau JC, Cavallini C, Ebrahim I, Petrov I, Kim J-H, Jeong M-H, Ramos Lopez GA, Laanmets P, Kovar F, Gaudin C, Fanouillere KC, Minini P, Hoffman EB, Moryusef A, Wiviott SD, Sabatine MS, Investigators TAO. 2013. Anticoagulation with otamixaban and ischemic events in non-ST-segment elevation acute coronary syndromes: the TAO randomized clinical trial. JAMA 310:1145–1155.
1.
Steg PG, van ’t Hof A, Clemmensen P, Lapostolle F, Dudek D, Hamon M, Cavallini C, Gordini G, Huber K, Coste P, Thicoipe M, Nibbe L, Steinmetz J, Ten Berg J, Eggink GJ, Zeymer U, Campo dell’ Orto M, Kanic V, Deliargyris EN, Day J, Schuette D, Hamm CW, Goldstein P. 2013. Design and methods of European Ambulance Acute Coronary Syndrome Angiography Trial (EUROMAX): an international randomized open-label ambulance trial of bivalirudin versus standard-of-care anticoagulation in patients with acute ST-segment-elevation myocardial infarction transferred for primary percutaneous coronary intervention. American Heart Journal 166:960–967.e6.
1.
Steg PG, van ’t Hof A, Hamm CW, Clemmensen P, Lapostolle F, Coste P, Ten Berg J, Van Grunsven P, Eggink GJ, Nibbe L, Zeymer U, Campo dell’ Orto M, Nef H, Steinmetz J, Soulat L, Huber K, Deliargyris EN, Bernstein D, Schuette D, Prats J, Clayton T, Pocock S, Hamon M, Goldstein P, Investigators E. 2013. Bivalirudin started during emergency transport for primary PCI. The New England Journal of Medicine 369:2207–2217.
1.
Udell JA, Steg PG, Bhatt DL. 2013. Impact of loneliness and living alone–reply. JAMA internal medicine 173:322–323.
1.
Wallentin L, Lopes RD, Hanna M, Thomas L, Hellkamp A, Nepal S, Hylek EM, Al-Khatib SM, Alexander JH, Alings M, Amerena J, Ansell J, Aylward P, Bartunek J, Commerford P, De Caterina R, Erol C, Harjola V-P, Held C, Horowitz JD, Huber K, Husted S, Keltai M, Lanas F, Lisheng L, McMurray JJV, Oh B-H, Rosenqvist M, Ruzyllo W, Steg PG, Vinereanu D, Xavier D, Granger CB, Apixaban for Reduction in S, Other Thromboembolic Events in Atrial Fibrillation I. 2013. Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation 127:2166–2176.
1.
Wiernik E, Pannier B, Czernichow S, Nabi H, Hanon O, Simon T, Simon J-M, Thomas F, Bean K, Consoli SM, Danchin N, Lemogne C. 2013. Occupational status moderates the association between current perceived stress and high blood pressure: evidence from the IPC cohort study. Hypertension (Dallas, Tex: 1979) 61:571–577.
1.
Zouggari Y, Ait-Oufella H, Bonnin P, Simon T, Sage AP, Guérin C, Vilar J, Caligiuri G, Tsiantoulas D, Laurans L, Dumeau E, Kotti S, Bruneval P, Charo IF, Binder CJ, Danchin N, Tedgui A, Tedder TF, Silvestre J-S, Mallat Z. 2013. B lymphocytes trigger monocyte mobilization and impair heart function after acute myocardial infarction. Nature Medicine 19:1273–1280.

2012

1.
Aissaoui N, Puymirat E, Tabone X, Charbonnier B, Schiele F, Lefèvre T, Durand E, Blanchard D, Simon T, Cambou J-P, Danchin N. 2012. Improved outcome of cardiogenic shock at the acute stage of myocardial infarction: a report from the USIK 1995, USIC 2000, and FAST-MI French nationwide registries. European Heart Journal 33:2535–2543.
1.
Ajzenberg N, Ducrocq G, Farnoud R, Huisse M-G, Alavoine L, Duval X, Mentré F, Steg PG. 2012. Recurrent acute coronary syndromes are associated with increased shear induced platelet aggregation. A case-control study. International Journal of Cardiology 155:313–314.
1.
Akerblom Å, Wallentin L, Siegbahn A, Becker RC, Budaj A, Buck K, Giannitsis E, Horrow J, Husted S, Katus HA, Steg PG, Storey RF, Åsenblad N, James SK. 2012. Cystatin C and estimated glomerular filtration rate as predictors for adverse outcome in patients with ST-elevation and non-ST-elevation acute coronary syndromes: results from the Platelet Inhibition and Patient Outcomes study. Clinical Chemistry 58:190–199.
1.
Amarenco P. 2012. Not all patients should be admitted to the hospital for observation after a transient ischemic attack. Stroke 43:1448–1449.
1.
Amarenco P, Labreuche J, Lavallée PC. 2012. Patients with transient ischemic attack with ABCD2 <4 can have similar 90-day stroke risk as patients with transient ischemic attack with ABCD2 ≥4. Stroke 43:863–865.
1.
Belle L, Labarère J, Fourny M, Drouet E, Mulak G, Dujardin J-J, Vilarem D, Bonnet P, Hanssen M, Simon T, Ferrières J, Danchin N, French registry of Acute ST elevation or non-ST elevation MI study investigators. 2012. Quality of care for myocardial infarction at academic and nonacademic hospitals. The American Journal of Medicine 125:365–373.
1.
Benyahia C, Gomez I, Kanyinda L, Boukais K, Danel C, Leséche G, Longrois D, Norel X. 2012. PGE(2) receptor (EP(4)) agonists: potent dilators of human bronchi and future asthma therapy? Pulmonary Pharmacology & Therapeutics 25:115–118.
1.
Boumendil A, Angus DC, Guitonneau A-L, Menn A-M, Ginsburg C, Takun K, Davido A, Masmoudi R, Doumenc B, Pateron D, Garrouste-Orgeas M, Somme D, Simon T, Aegerter P, Guidet B, group I-C study. 2012. Variability of intensive care admission decisions for the very elderly. PloS One 7:e34387.
1.
Chevreul K, Prigent A, Durand-Zaleski I, Steg PG. 2012. Does lay media ranking of hospitals reflect lower mortality in treating acute myocardial infarction? Archives of Cardiovascular Diseases 105:489–498.
1.
Chiang C-E, Naditch-Brûlé L, Murin J, Goethals M, Inoue H, O’Neill J, Silva-Cardoso J, Zharinov O, Gamra H, Alam S, Ponikowski P, Lewalter T, Rosenqvist M, Steg PG. 2012. Distribution and risk profile of paroxysmal, persistent, and permanent atrial fibrillation in routine clinical practice: insight from the real-life global survey evaluating patients with atrial fibrillation international registry. Circulation Arrhythmia and Electrophysiology 5:632–639.
1.
Cueff C, Keenan NG, Krapf L, Steg PG, Cimadevilla C, Ducrocq G, Michel J-B, Vahanian A, Messika-Zeitoun D. 2012. Screening for abdominal aortic aneurysm in coronary care unit patients with acute myocardial infarction using portable transthoracic echocardiography. European Heart Journal Cardiovascular Imaging 13:574–578.
1.
Dallongeville J, Banegas JR, Tubach F, Guallar E, Borghi C, De Backer G, Halcox JPJ, Massó-González EL, Perk J, Sazova O, Steg PG, Artalejo FR, Investigators E. 2012. Survey of physicians’ practices in the control of cardiovascular risk factors: the EURIKA study. European Journal of Preventive Cardiology 19:541–550.
1.
Damy T, Burgel P-R, Pepin J-L, Boelle P-Y, Cracowski C, Murris-Espin M, Nove-Josserand R, Stremler N, Simon T, Adnot S, Fauroux B. 2012. Pulmonary acceleration time to optimize the timing of lung transplant in cystic fibrosis. Pulmonary Circulation 2:75–83.
1.
Danchin N, Simon T. 2012. Women are the equal of men at last... for sure? EuroIntervention: Journal of EuroPCR in Collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology 8:883–885.
1.
Dimopoulos K, Dudek D, Piscione F, Mielecki W, Savonitto S, Borgia F, Murena E, Manari A, Gaspardone A, Ochala A, Zmudka K, Bolognese L, Steg PG, Flather M, Di Mario C, Investigators CA-AMI. 2012. Timing of events in STEMI patients treated with immediate PCI or standard medical therapy: implications on optimisation of timing of treatment from the CARESS-in-AMI trial. International Journal of Cardiology 154:275–281.
1.
Fauroux B, Pepin J-L, Boelle P-Y, Cracowski C, Murris-Espin M, Nove-Josserand R, Stremler N, Simon T, Burgel P-R. 2012. Sleep quality and nocturnal hypoxaemia and hypercapnia in children and young adults with cystic fibrosis. Archives of Disease in Childhood 97:960–966.
1.
Foudi N, Gomez I, Benyahia C, Longrois D, Norel X. 2012. Prostaglandin E2 receptor subtypes in human blood and vascular cells. European Journal of Pharmacology 695:1–6.
1.
Hanssen M, Cottin Y, Khalife K, Hammer L, Goldstein P, Puymirat E, Mulak G, Drouet E, Pace B, Schultz E, Bataille V, Ferrières J, Simon T, Danchin N, Investigators F-M. 2012. French Registry on Acute ST-elevation and non ST-elevation Myocardial Infarction 2010. FAST-MI 2010. Heart (British Cardiac Society) 98:699–705.
1.
Juillière Y, Cambou JP, Bataille V, Mulak G, Galinier M, Gibelin P, Benamer H, Bouvaist H, Méneveau N, Tabone X, Simon T, Danchin N, Investigators F-M. 2012. Heart failure in acute myocardial infarction: a comparison between patients with or without heart failure criteria from the FAST-MI registry. Revista Espanola De Cardiologia (English Ed) 65:326–333.
1.
Leseche G, Alsac J-M, Houbbalah R, Castier Y, Fady F, Mazighi M, Amarenco P. 2012. Carotid endarterectomy in the acute phase of stroke-in-evolution is safe and effective in selected patients. Journal of Vascular Surgery 55:701–707.
1.
Lind L, Simon T, Johansson L, Kotti S, Hansen T, Machecourt J, Ninio E, Tedgui A, Danchin N, Ahlström H, Mallat Z. 2012. Circulating levels of secretory- and lipoprotein-associated phospholipase A2 activities: relation to atherosclerotic plaques and future all-cause mortality. European Heart Journal 33:2946–2954.
1.
Longrois D, Gomez I, Foudi N, Topal G, Dhaouadi M, Kotelevets L, Chastre E, Norel X. 2012. Prostaglandin E₂ induced contraction of human intercostal arteries is mediated by the EP₃ receptor. European Journal of Pharmacology 681:55–59.
1.
Mazighi M, Meseguer E, Labreuche J, Amarenco P. 2012. Bridging therapy in acute ischemic stroke: a systematic review and meta-analysis. Stroke 43:1302–1308.
1.
Mazighi M, Meseguer E, Labreuche J, Serfaty J-M, Laissy J-P, Lavallée PC, Cabrejo L, Guidoux C, Lapergue B, Klein IF, Olivot J-M, Rouchaud A, Desilles J-P, Schouman-Claeys E, Amarenco P. 2012. Dramatic recovery in acute ischemic stroke is associated with arterial recanalization grade and speed. Stroke 43:2998–3002.
1.
Mehran R, Steg PG, White HD, Rao SV. 2012. Letter by Mehran et al regarding article, “Bleeding academic research consortium consensus report: the food and drug administration perspective.” Circulation 125:e460.
1.
Mehta SR, Jolly SS, Cairns J, Niemela K, Rao SV, Cheema AN, Steg PG, Cantor WJ, Džavík V, Budaj A, Rokoss M, Valentin V, Gao P, Yusuf S, Investigators R. 2012. Effects of radial versus femoral artery access in patients with acute coronary syndromes with or without ST-segment elevation. Journal of the American College of Cardiology 60:2490–2499.
1.
Meseguer E, Mazighi M, Lapergue B, Labreuche J, Sirimarco G, Gonzalez-Valcarcel J, Lavallée PC, Cabrejo L, Guidoux C, Klein IF, Olivot J-M, Rouchaud A, Desilles J-P, Amarenco P. 2012. Outcomes after thrombolysis in AIS according to prior statin use: a registry and review. Neurology 79:1817–1823.
1.
Moreno JA, Ortega-Gómez A, Delbosc S, Beaufort N, Sorbets E, Louedec L, Esposito-Farèse M, Tubach F, Nicoletti A, Steg PG, Michel J-B, Feldman L, Meilhac O. 2012. In vitro and in vivo evidence for the role of elastase shedding of CD163 in human atherothrombosis. European Heart Journal 33:252–263.
1.
Mounier-Vehier C, Simon T, Guedj-Meynier D, Ferrini M, Ghannad E, Hubermann J-P, Jullien G, Poncelet P, Achouba A, Quéré S, Guenoun M. 2012. Gender-related differences in the management of hypertension by cardiologists: the PARITE study. Archives of Cardiovascular Diseases 105:271–280.
1.
Puymirat É, Aissaoui N, Silvain J, Bonello L, Cuisset T, Motreff P, Bataille V, Durand E, Cottin Y, Simon T, Danchin N, investigators F-M. 2012. Comparison of bleeding complications and 3-year survival with low-molecular-weight heparin versus unfractionated heparin for acute myocardial infarction: the FAST-MI registry. Archives of Cardiovascular Diseases 105:347–354.
1.
Puymirat E, Simon T, Steg PG, Schiele F, Guéret P, Blanchard D, Khalife K, Goldstein P, Cattan S, Vaur L, Cambou J-P, Ferrières J, Danchin N, Investigators UU, Investigators FM. 2012. Association of changes in clinical characteristics and management with improvement in survival among patients with ST-elevation myocardial infarction. JAMA 308:998–1006.
1.
Puymirat E, Taldir G, Aissaoui N, Lemesle G, Lorgis L, Cuisset T, Bourlard P, Maillier B, Ducrocq G, Ferrieres J, Simon T, Danchin N. 2012. Use of invasive strategy in non-ST-segment elevation myocardial infarction is a major determinant of improved long-term survival: FAST-MI (French Registry of Acute Coronary Syndrome). JACC Cardiovascular interventions 5:893–902.
1.
Reynolds HR, Forman SA, Tamis-Holland JE, Steg PG, Mark DB, Pearte CA, Carvalho AC, Sopko G, Liu L, Lamas GA, Kruk M, Loboz-Grudzien K, Ruzyllo W, Hochman JS. 2012. Relationship of female sex to outcomes after myocardial infarction with persistent total occlusion of the infarct artery: analysis of the Occluded Artery Trial (OAT). American Heart Journal 163:462–469.
1.
Schiano P, Steg PG, Barbou F, Monségu J. 2012. A strategy for addressing aspirin hypersensitivity in patients requiring urgent PCI. European Heart Journal Acute Cardiovascular Care 1:75–78.
1.
Sokol H, Beaugerie L, Maynadié M, Laharie D, Dupas J-L, Flourié B, Lerebours E, Peyrin-Biroulet L, Allez M, Simon T, Carrat F, Brousse N, Group CS. 2012. Excess primary intestinal lymphoproliferative disorders in patients with inflammatory bowel disease. Inflammatory Bowel Diseases 18:2063–2071.
1.
Steg PG, Mehta SR, Pollack CV, Bode C, Gaudin C, Fanouillere K, Moryusef A, Wiviott SD, Sabatine MS. 2012. Design and rationale of the treatment of acute coronary syndromes with otamixaban trial: a double-blind triple-dummy 2-stage randomized trial comparing otamixaban to unfractionated heparin and eptifibatide in non-ST-segment elevation acute coronary syndromes with a planned early invasive strategy. American Heart Journal 164:817–824.e13.
1.
Udell JA, Steg PG, Scirica BM, Smith SC, Ohman EM, Eagle KA, Goto S, Cho JI, Bhatt DL, Investigators RE of A for CHR. 2012. Living alone and cardiovascular risk in outpatients at risk of or with atherothrombosis. Archives of Internal Medicine 172:1086–1095.
1.
White HD, Reynolds HR, Carvalho AC, Pearte CA, Liu L, Martin CE, Knatterud GL, Džavík V, Kruk M, Steg PG, Cantor WJ, Menon V, Lamas GA, Hochman JS. 2012. Reinfarction after percutaneous coronary intervention or medical management using the universal definition in patients with total occlusion after myocardial infarction: results from long-term follow-up of the Occluded Artery Trial (OAT) cohort. American Heart Journal 163:563–571.
1.
von Elverfeldt D, von zur Muhlen C, Wiens K, Neudorfer I, Zirlik A, Meissner M, Tilly P, Charles A-L, Bode C, Peter K, Fabre J-E. 2012. In vivo detection of activated platelets allows characterizing rupture of atherosclerotic plaques with molecular magnetic resonance imaging in mice. PloS One 7:e45008.

2 thoughts on “Team 5: Atherothrombotic Disease in Heart and Brain

  1. Pingback: Early detection of strokes

  2. Pingback: Stroke: locate, react, restore

Comments are closed.